C:\Program Files\Stnexp\Queries\09938754.str



L2



chain nodes :
19 20 22 23 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-22 6-19 8-20 12-26 13-25 14-23
ring bonds :
1-2 1-14 2-3 3-4 4-5 4-15 5-6 5-18 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14
15-16 16-17 17-18
exact/norm bonds :
1-2 1-14 1-22 2-3 3-4 5-6 6-7 6-19 7-8 8-9 9-10 10-11 11-12 12-13 12-26
13-14 13-25 14-23
exact bonds :
8-20
normalized bonds :
4-5 4-15 5-18 15-16 16-17 17-18

G1:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 22:CLASS
23:CLASS 25:CLASS 26:CLASS

C:\Program Files\Stnexp\Queries\09938754a.str



not

L33



chain nodes :
19 20 22 23 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-22 6-19 8-20 12-26 13-25 14-23
ring bonds :
1-2 1-14 2-3 3-4 4-5 4-15 5-6 5-18 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14
15-16 16-17 17-18
exact/norm bonds :
1-2 1-14 1-22 2-3 3-4 5-6 6-7 6-19 7-8 8-9 9-10 10-11 11-12 12-13 12-26
13-14 13-25 14-23
exact bonds :
8-20
normalized bonds :
4-5 4-15 5-18 15-16 16-17 17-18

G1:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 22:CLASS
23:CLASS 25:CLASS 26:CLASS

C:\Program Files\Stnexp\Queries\09938754a.str



not

L40



chain nodes :
19 20 22 23 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
1-22 2-26 6-19 8-20 13-25 14-23
ring bonds :
1-2 1-14 2-3 3-4 4-5 4-15 5-6 5-18 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14
15-16 16-17 17-18
exact/norm bonds :
1-2 1-14 1-22 2-3 3-4 5-6 6-7 6-19 7-8 8-9 9-10 10-11 11-12 12-13 13-14
13-25 14-23
exact bonds :
2-26 8-20
normalized bonds :
4-5 4-15 5-18 15-16 16-17 17-18

G1:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 22:CLASS
23:CLASS 25:CLASS 26:CLASS

```
=> d his

     (FILE 'HOME' ENTERED AT 10:36:21 ON 29 APR 2004)

     FILE 'STNGUIDE' ENTERED AT 10:36:32 ON 29 APR 2004

     FILE 'HOME' ENTERED AT 10:36:35 ON 29 APR 2004

     FILE 'REGISTRY' ENTERED AT 10:36:37 ON 29 APR 2004
L1             STRUCTURE UPLOADED
L2             QUE L1
L3           5 S L2
L4         480 S 3-6-14/SZ
L5        3359 S 6-14/SZ
L6           1 S 12772-57-5/RN
L7          69 S L5 AND SPIRO
L8        2746 S 6-6-14/SZ
L9          24 S 3-6-6-14/SZ
L10       6593 S L4 OR L5 OR L8 OR L9
L11         42 S L2  SUB=L10 SAM
L12        797 S L2  SUB=L10 FUL

     FILE 'CAPLUS' ENTERED AT 10:42:51 ON 29 APR 2004
L13       1070 S L12
L14        ANALYZE L13 1- RN HIT :     761 TERMS

     FILE 'REGISTRY' ENTERED AT 10:45:30 ON 29 APR 2004
L15       1050 S 26538?/RN
L16       1056 S 36455?/RN
L17       1095 S 12772?/RN
L18         99 S 71030?/RN
L19       1045 S 42422?/RN
L20         71 S 5916-?/RN
L21         54 S 7344-?/RN
L22       1064 S 13040?/RN
L23          1 S L12 AND L15
L24          2 S L12 AND L16
L25          1 S L12 AND L17
L26          1 S L12 AND L18
L27          1 S L12 AND L19
L28         14 S L12 AND L20
L29          7 S L12 AND L21
L30          1 S L12 AND L22
L31         28 S L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30
L32            STRUCTURE UPLOADED
L33            QUE L32
L34         12 S L33  SUB=L12 SAM
L35        249 S L33  SUB=L12 FUL
L36        548 S L12 NOT L35

     FILE 'CAPLUS' ENTERED AT 10:53:49 ON 29 APR 2004
L37        224 S L36
L38        ANALYZE L37 1- RN HIT :     537 TERMS

     FILE 'REGISTRY' ENTERED AT 10:55:47 ON 29 APR 2004
L39            STRUCTURE UPLOADED
L40            QUE L39
L41          1 S L40  SUB=L36 SAM
```

```
L42          20 S L40  SUB=L36 FUL
L43         528 S L36 NOT L42

     FILE 'CAPLUS' ENTERED AT 10:57:09 ON 29 APR 2004
L44          214 S L43
L45          ANALYZE L44 1- RN HIT :      520 TERMS

     FILE 'REGISTRY' ENTERED AT 10:59:05 ON 29 APR 2004
L46           19 S L31 AND L35
L47            6 S L42 AND L31
L48           25 S L46 OR L47
L49            3 S L31 NOT L48
L50          525 S L43 NOT L49

     FILE 'CAPLUS' ENTERED AT 11:00:45 ON 29 APR 2004
L51           72 S L50
L52           36 S L51 AND PATENT/DT
L53           36 S L51 NOT L52
L54            0 S L53 AND 2004/SO
L55            8 S L53 AND 2003/SO
L56            4 S L53 AND 2002/SO
L57            5 S L53 AND 2001/SO
L58            3 S L53 AND 2000/SO
L59           55 S L51 NOT (L55 OR L56 OR L57)

=> d l2
L2 HAS NO ANSWERS
L1                STR
```



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

=> d l33
L33 HAS NO ANSWERS
L32 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.
L33 QUE ABB=ON PLU=ON L32

=> d l40
L40 HAS NO ANSWERS
L39 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.
L40 QUE ABB=ON PLU=ON L39

=> d ibib abs hitstr l59 1-55

L59 ANSWER 1 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:252337 CAPLUS
DOCUMENT NUMBER: 140:287285
TITLE: Preparation of cyclic benzoic acid esters as Hsp90 family protein inhibitors and antitumor agents
INVENTOR(S): Kitamura, Yushi; Kanda, Yutaka; Onodera, Hideyuki; Soga, Shiro; Kusaka, Hideaki
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024142	A1	20040325	WO 2003-JP11088	20030829

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-250057 A 20020829
GI


I


II

AB Disclosed are Hsp90 family protein inhibitors, therapeutic agents for diseases related to Hsp90 family protein, or antitumor agents comprising as the active ingredients cyclic benzoic acid derivs. (α- or β-zearalanol or zearalanone derivs.) represented by the following general formula (I) or its pharmacol. acceptable salt [wherein R1-R4 = H, HO, optionally substituted lower alkyl, etc.; X = O, S, or (un)substituted NH; a = -(CRalRa2)m-, -CHRa3CRa4Ra5- or -CHRa6Y-; b = -(CRb1Rb2)n- ; c = -(CHRc1CHRc2)p- or -CHRc3Z- ; d = -CRd1CRd2- or -NRd4CO-; e = -CRe1Re2- or -CHRe3CHRe4-; f = -(CRf1Rf2)q-; g = -CRg1Rg2-; m, n, p, = an integer of 0-5; Ra1, Ra2, Rb1, Rb2, Rc3, Re1, Re2, Rf1, Rf2, Rg1, Rg2= H, HO, each (un)substituted lower alkoxy, lower alkanoyloxy, or lower alkyl; Ra3-Ra6, Re3, Re4 = H, HO, CO2H, each (un)substituted lower alkoxy, lower

L59 ANSWER 1 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 675588-37-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[(3S,7S)-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-bis(methoxymethoxy)-3-methyl-1-oxo-1H-2-benzoxacyclotetradecin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 1 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
alkanoyloxy, lower alkoxycarbonyl, or lower alkylaminocarbonyl, etc.: Rc1, Rc2 = H, HO, each (un)substituted lower alkoxy or lower alkanoyloxy, etc.; Y, Z = a group listed in X; Rd1, Rd2 = H, HO, halo, cyano, NH2, each (un)substituted alkoxy, aralkyloxy, aryloxy, etc.]. Thus, 31.1 mg α-zearalanol was dissolved in 5.0 mL CH2Cl2, treated with 105 mg 4-dimethylaminopyridine and 0.100 mL Ac2O, and stirred at room temp. for 11 h to give, after purifn. on TLC, 80% α-zearalanol acetate (II). All the 23 compds. prepd. including II at 100 μmol/L inhibited by ≥30% the binding of biotinylated radisicol to Hsp90 family protein. Pharmaceutical formulations, e.g a tablet contg. II, were prepd.
IT **675588-32-6P 675588-33-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic benzoic acid esters as Hsp90 family protein inhibitors and antitumor agents)
RN 675588-32-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 7-amino-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-, (3S,7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 675588-33-7 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[(3S,7S)-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo-1H-2-benzoxacyclotetradecin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **675588-37-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclic benzoic acid esters as Hsp90 family protein inhibitors and antitumor agents)

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:836804 CAPLUS
DOCUMENT NUMBER: 139:341427
TITLE: Hair growth stimulant containing WNT-5A inhibitors, and method for screening hair papilla cell growth promoter
INVENTOR(S): Ikeda, Akiko; Shinonaga, Hideki; Fujimoto, Natsuko; Kasai, Yoko
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086334	A1	20031023	WO 2003-JP4884	20030417

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-115529 A 20020417
OTHER SOURCE(S): MARPAT 139:341427
AB Disclosed are a hair papilla cell growth promoter, a hair growth stimulant and a hair growth tonic containing a compound having an activity of inhibiting the function of protein WNT-5A. The inhibitory effect on WNT-5A and promotive effect on hair papilla cell proliferation of radicicol were examined in cultured human hair papilla cell. Also, hair growth stimulants of the present invention were isolated from culture product of Pochnoia chlamydosporia chlamydosporia TF-0480.
IT **75207-11-3P 75207-15-7P**
RL: BPN (Biosynthetic preparation); COS (Cosmetic use); PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(hair growth stimulant containing WNT-5A inhibitors, and method for screening hair papilla cell growth promoter)
RN 75207-11-3 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 75207-15-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,7,8-tetrahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



IT **75207-14-6P 194085-01-3P 459126-69-3P 616899-75-3P 616899-76-4P 616899-79-7P 616899-82-2P 617693-60-4P**
RL: BPN (Biosynthetic preparation); COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hair growth stimulant containing WNT-5A inhibitors, and method for screening hair papilla cell growth promoter)
RN 75207-14-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,7,8,9,10-hexahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 194085-01-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6-tetrahydro-5,14,16-trihydroxy-6-methoxy-3-methyl-, (3R,5S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 616899-79-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,7,8,9,10-hexahydro-14,16-dihydroxy-3-methyl-, (5E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 616899-82-2 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-3,9,11-trihydroxy-14-methyl- (9CI) (CA INDEX NAME)



RN 617693-60-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-11-hydroxy-14-methyl-9-β-D-ribofuranosyl-, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **616899-27-5P 616899-29-7P 616899-30-0P**
RL: COS (Cosmetic use); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(hair growth stimulant containing WNT-5A inhibitors, and method for screening hair papilla cell growth promoter)
RN 616899-27-5 CAPLUS

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 459126-69-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 616899-75-3 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-3,9,11-trihydroxy-14-methyl-, (1aS,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-76-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,7,8-tetrahydro-14,16-dihydroxy-3-methyl-, (5E,9E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aS,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616899-29-7 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6,9,11-trihydroxy-14-methyl-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-30-0 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6,9,11-trihydroxy-14-methyl-, (1aS,4E,6S,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **184537-25-5P 544709-83-3P 616899-25-3P**
616899-26-4P 616899-28-6P 616899-31-1P
616899-32-2P 616899-33-3P 616899-34-4P
616899-35-5P 616899-36-6P 616899-37-7P
616899-38-8P 616899-45-7P 616899-46-8P
616899-47-9P 616899-48-0P 616899-49-1P
616899-50-4P 616899-53-7P 616899-57-1P
616899-58-2P 616899-59-3P 616899-60-6P
616899-61-7P 616899-62-8P 616899-63-9P
616899-64-0P 616899-65-1P 616899-66-2P
616899-67-3P 616899-71-9P 616899-72-0P
616899-73-1P 616899-74-2P 617693-56-8P
617693-57-9P
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hair growth stimulant containing WNT-5A inhibitors, and method for screening hair papilla cell growth promoter)

RN 184537-25-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-oxime, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 544709-83-3 CAPLUS

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6,7,8,9,10-octahydro-5,14,16-trihydroxy-3-methyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616899-25-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 9,11-bis(acetyloxy)-8-chloro-1a,14,15,15a-tetrahydro-14-methyl-, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-26-4 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aS,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-28-6 CAPLUS

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,6,7,14,15,15a-hexahydro-6,9,11-trihydroxy-14-methyl-, (1aS,2Z,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-31-1 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,4,5,6,7,14,15,15a-decahydro-6,9,11-trihydroxy-14-methyl-, (1aS,6S,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616899-32-2 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,4,5,6,7,14,15,15a-decahydro-6,9,11-trihydroxy-14-methyl-, (1aS,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 616899-33-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dimethoxy-14-methyl-, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-34-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-3,4,5,6-tetrahydro-5,14,16-trihydroxy-3-methyl-, (3R,5S,6S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-35-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-3,4,5,6-tetrahydro-5,14,16-trihydroxy-3-methyl-, (3R,5S,6R,7Z,9E)- (9CI) (CA INDEX NAME)

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-36-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6-tetrahydro-5,6,14,16-tetrahydroxy-3-methyl-, (3R,5S,6S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-37-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6-tetrahydro-5,6,14,16-tetrahydroxy-3-methyl-, (3R,5S,6R,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-38-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-5-(formyloxy)-3,4,5,6-tetrahydro-14,16-dihydroxy-3-methyl-, (3R,5S,6S,7Z,9E)- (9CI) (CA INDEX NAME)

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-45-7 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6,11-dihydroxy-9-methoxy-14-methyl-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-46-8 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6-hydroxy-9,11-dimethoxy-14-methyl-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 616899-47-9 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 6,9,11-tris(acetyloxy)-8-chloro-1a,2,3,6,7,14,15,15a-octahydro-14-methyl-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-48-0 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6,11-dihydroxy-9-methoxy-14-methyl-, (1aS,4E,6S,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 616899-49-1 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6-hydroxy-9,11-dimethoxy-14-methyl-, (1aS,4E,6S,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-50-4 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 6,9,11-tris(acetyloxy)-8-chloro-1a,2,3,6,7,14,15,15a-octahydro-14-methyl-, (1aS,4E,6S,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 616899-53-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6,9,10-hexahydro-5,14,16-trihydroxy-3-methyl-, (3R,7Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-57-1 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 9-butoxy-8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6,11-dihydroxy-14-methyl-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 616899-58-2 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 9,11-dibutoxy-8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6-hydroxy-14-methyl-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-59-3 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 11-butoxy-8-chloro-9-(hexyloxy)-1a,2,3,6,7,14,15,15a-octahydro-6-hydroxy-14-methyl-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 616899-60-6 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-9,11-bis(hexyloxy)-1a,2,3,6,7,14,15,15a-octahydro-6-hydroxy-14-methyl-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-B



RN 616899-61-7 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6-hydroxy-14-methyl-9,11-dipropoxy-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-62-8 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 8-chloro-1a,2,3,6,7,14,15,15a-octahydro-6-hydroxy-14-methyl-9,11-bis(phenylmethoxy)-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A

PAGE 1-B



RN 616899-63-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 6-bromo-13-chloro-3,4,5,6,7,8,11,12-octahydro-5,11,14,16-tetrahydroxy-3-methyl-, (3R,5S,6R,9E,11R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 616899-64-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,7,8,11,12-hexahydro-11,14,16-trihydroxy-3-methyl-, (5E,9E,11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 616899-65-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,7,8,11,12-hexahydro-11,14,16-trihydroxy-3-methyl-, (5E,9E,11R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 616899-66-2 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-12-one, 1a,2,3,6,7,14,15,15a-octahydro-6,9,11-trihydroxy-14-methyl-, (1aS,4E,6R,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-67-3 CAPLUS
CN Ethanethioic acid, 2,2'-[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl]bis(oxy)]bis-, S,S'-diphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-71-9 CAPLUS
CN Acetic acid, 2,2'-[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
diyl]bis(oxy)]bis-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-72-0 CAPLUS
CN Acetic acid, 2,2'-[[(1aS,4E,6R,14R,15aS)-8-chloro-1a,3,6,7,12,14,15,15a-octahydro-6-hydroxy-14-methyl-12-oxo-2H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl]bis(oxy)]bis-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-B



RN 616899-73-1 CAPLUS
CN 3-Pyridinecarboxylic acid, (1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 616899-74-2 CAPLUS
CN Acetic acid, 2,2'-[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl]bis(oxy)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 617693-56-8 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, (1aS,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 617693-57-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,5,6,7,8,9,10-octahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:299004 CAPLUS
DOCUMENT NUMBER: 138:314573
TITLE: Antirheumatic agents and apoptosis promoters containing radicicols, and their preparation
INVENTOR(S): Ichimura, Michiaki; Akasaka, Kazuto; Yamazaki, Motoo; Ino, Yoji; Amishiro, Nobuyoshi; Murakata, Isamu; Honma, Ko
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 45 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003113183	A2	20030418	JP 2001-309431	20011005
PRIORITY APPLN. INFO.:			JP 2001-309431	20011005

OTHER SOURCE(S): MARPAT 138:314573
G1



I

AB Title agents and promoters contain radicicols I [R1, R2 = H, (un)substituted alkenoyl, (un)substituted alkadi- or trienoyl, trialkylsilyl, triarylsilyl, (un)substituted (cyclo)alkyl, (un)substituted amino, (un)substituted alkoxy, etc.; R3 = H, halo, (un)substituted alkyl, (un)substituted aminoalkyl, OH, (un)substituted alkoxy, etc.; R4 = H, halo; AB = Q or its analogous group; Y2 = O, NOH, (un)substituted alkenyloxyimino, etc.; R15 = halo; R16 = H, (un)substituted alkanoyl, (un)substituted alkenoyl, alkadi- or trienoyl, etc.; R15R16 may form single bond] or their pharmacol. acceptable salts as active ingredients. Thus, I (R1-R3 = H, R4 = Cl, AB = Q, Y2 = NOH, R15R16 = bond) enhanced Fas-induced apoptosis in the presence of CH-11.
IT **75207-12-4P 88929-18-4P, Tetrahydroradicicol**
511530-78-2P 511530-79-3P 511530-80-6P
511530-81-7P 511530-82-8P 511530-83-9P
511530-84-0P 511530-85-1P 511530-87-3P
511530-88-4P 511530-89-5P 511530-90-8P
511530-91-9P 511530-92-0P 511530-93-1P
511530-94-2P 511530-95-3P 511530-96-4P
511530-97-5P 511530-98-6P 511530-99-7P
511531-08-1P 511531-09-2P 511531-12-7P
511531-13-8P 511531-14-9P 511531-15-0P
511531-19-4P 511531-20-7P 511531-21-8P
511531-22-9P 511531-23-0P 511531-24-1P
511531-25-2P 511531-26-3P 511531-27-4P

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
511531-28-5P 511531-29-6P 511531-30-9P
511531-31-0P 511531-32-1P 511531-33-2P
511531-34-3P 511531-35-4P 511531-36-5P
511531-37-6P 511531-38-7P 511531-39-8P
511531-40-1P 511531-41-2P 511531-42-3P
511531-43-4P 511531-44-5P 511531-45-6P
511531-46-7P 511531-47-8P 511531-48-9P
511531-49-0P 511531-50-3P 511531-51-4P
511531-52-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(radicicols as antirheumatic agents and promoters of Fas-induced apoptosis)
RN 75207-12-4 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, (1aS,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



RN 88929-18-4 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, (1aR,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 511530-78-2 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, 6-oxime, (1aR,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511530-79-3 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, 6-[O-(3-hydroxypropyl)oxime], (1aR,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 511530-80-6 CAPLUS
CN Piperidine, 1-[[[[(1aR,14R,15aR)-8-chloro-1a,2,3,4,5,7,12,14,15,15a-decahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511530-84-0 CAPLUS
CN Benzoic acid, 3-methoxy-, [(1aR,14R,15aR)-8-chloro-1a,2,3,4,5,7,12,14,15,15a-decahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 511530-85-1 CAPLUS
CN 3-Pyridinecarboxylic acid, [(1aR,14R,15aR)-8-chloro-1a,2,3,4,5,7,12,14,15,15a-decahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 511530-81-7 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,6Z,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511530-82-8 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, 6-[O-(2-pyridinylmethyl)oxime], (1aR,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 511530-83-9 CAPLUS
CN 12H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H)-dione, 8-chloro-1a,2,4,5,7,14,15,15a-octahydro-9,11-dihydroxy-14-methyl-, 6-hydrazone, (1aR,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511530-87-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8,10-dichloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511530-88-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 10-bromo-8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 511530-89-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-10-(hydroxymethyl)-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511530-90-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-10-(methoxymethyl)-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511530-91-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-10-[(4-methoxyphenoxy)methyl]-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511530-92-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-10-carboxaldehyde, 8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-, (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511530-93-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-10,14-dimethyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511530-94-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-10-[(ethylthio)methyl]-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511530-95-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-10-[(ethylsulfonyl)methyl]-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511530-96-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-10-[[[2-(dimethylamino)ethyl]methylamino]methyl]-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511530-97-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-10-[(dimethylamino)methyl]-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511530-98-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-10-[[[2-(dimethylamino)ethyl]amino]methyl]-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511530-99-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-10-[[[2-(dimethylamino)ethyl]methylamino]methyl]-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-08-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-15-[(dimethylamino)methyl]-3,4,5,6-tetrahydro-5,6,14,16-tetrahydroxy-3-methyl-, (3R,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-09-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6-tetrahydro-5,6,14,16-tetrahydroxy-3-methyl-, 11-oxime, (3R,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 511531-12-7 CAPLUS
CN [2]Benzoxacyclotetradecino[5,6-b]azirine-6,12(1H,7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (2Z,4E,6E,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-13-8 CAPLUS
CN 6H-Thiireno[2,3-e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (2Z,4E,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-14-9 CAPLUS
CN 6H-Thiireno[2,3-e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (2Z,4E,6E,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-15-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6-tetrahydro-5,6,14,16-tetrahydroxy-3-methyl-, (3R,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-19-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,5,11(6H,12H)-trione, 13-chloro-3,4-dihydro-14,16-dihydroxy-3-methyl-, 11-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (3R,7Z,9E,11E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 511531-20-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,5,11(6H,12H)-trione, 13-chloro-3,4-dihydro-14,16-dihydroxy-3-methyl-, 5-oxime 11-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (3R,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-21-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,5,11(6H,12H)-trione, 13-chloro-3,4-dihydro-14,16-dihydroxy-3-methyl-, 5-(O-methyloxime) 11-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (3R,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-22-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,5,11(6H,12H)-trione, 13-chloro-3,4-dihydro-14,16-dihydroxy-3-methyl-, 5,11-bis[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (3R,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 511531-25-2 CAPLUS
CN Acetic acid, [[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-12-oxo-6-[[2-oxo-2-(1-piperidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-26-3 CAPLUS
CN Piperidine, 1-[[[[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-12-oxo-9,11-bis(3-pyridinylmethoxy)-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-27-4 CAPLUS

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-23-0 CAPLUS
CN Acetic acid, [[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-24-1 CAPLUS
CN Acetic acid, 2,2'-[[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl]bis(oxy)]bis-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Benzoic acid, 4-bromo-, (1aR,2Z,4E,6E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-28-5 CAPLUS
CN Benzoic acid, 4-bromo-, (1aR,2Z,4E,6E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-29-6 CAPLUS
CN Benzoic acid, 4-bromo-, (1aR,2Z,4E,6E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-30-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9-ethoxy-1a,14,15,15a-tetrahydro-11-hydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-31-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-11-hydroxy-14-methyl-9-(2-propenyloxy)-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-34-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-11-hydroxy-14-methyl-9-[(tetrahydro-2H-pyran-2-yl)oxy]-, 6-oxime, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-35-4 CAPLUS
CN Carbamic acid, propyl-, (1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-12-oxo-6-[[2-oxo-2-(1-piperidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Double bond geometry as shown.



RN 511531-32-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-11-hydroxy-9-(methoxymethoxy)-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-33-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-11-hydroxy-14-methyl-9-[(tetrahydro-2H-pyran-2-yl)oxy]-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 511531-36-5 CAPLUS
CN Carbamic acid, propyl-, (1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-12-oxo-6-[[2-oxo-2-(1-piperidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-37-6 CAPLUS
CN Carbamic acid, [4-(dimethylamino)phenyl]-, (1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-12-oxo-6-[[2-oxo-2-(1-piperidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-38-7 CAPLUS
CN Carbamic acid, 3-pyridinyl-, (1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-12-oxo-6-[[2-oxo-2-(1-piperidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-41-2 CAPLUS
CN β-D-Glucopyranosiduronic acid, (1aR,2Z,4E,6E,14R,15aR)-9-[(4-bromobenzoyl)oxy]-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-42-3 CAPLUS
CN β-D-Glucopyranosiduronic acid, (1aR,2Z,4E,6E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 511531-39-8 CAPLUS
CN Piperidine, 1-[[[[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-9,11-bis[(methylsulfonyl)oxy]-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-40-1 CAPLUS
CN β-D-Glucopyranosiduronic acid, (1aR,2Z,4E,6E,14R,15aR)-11-[(4-bromobenzoyl)oxy]-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-43-4 CAPLUS
CN β-D-Glucopyranosiduronic acid, (1aR,2Z,4E,6E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-44-5 CAPLUS
CN β-D-Glucopyranosiduronic acid, (1aR,2Z,4E,6E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-45-6 CAPLUS
CN β-D-Glucopyranosiduronic acid, (1aR,2Z,4E,6E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-46-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-11-hydroxy-9-methoxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-49-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9-hydroxy-14-methyl-11-[[2-(trimethylsilyl)ethoxy]methoxy]-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-50-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-methyl-, (1aR,2Z,4E,6E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-47-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-11-hydroxy-9-(2-hydroxyethoxy)-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-48-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-bis(2-hydroxyethoxy)-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-51-4 CAPLUS
CN Benzenesulfonamide, 4-[[[[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-52-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methyl]oxime], (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **501124-40-9 511530-86-2 511531-00-3**
511531-01-4 511531-02-5 511531-03-6
511531-04-7 511531-05-8 511531-06-9
511531-07-0 511531-53-6 511531-54-7
511531-55-8 511531-56-9 511531-57-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(radicicols as antirheumatic agents and promoters of Fas-induced apoptosis)

RN 501124-40-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-oxime, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511530-86-2 CAPLUS
CN Piperidine, 1-[[[[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-00-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-10-[[(2-hydroxyethyl)methylamino]methyl]-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-01-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-10-[[methyl(phenylmethyl)amino]methyl]-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-02-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-10-[(cyclopentylamino)methyl]-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-03-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-10-(1-pyrrolidinylmethyl)-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-04-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-10-[(3-hydroxy-1-pyrrolidinyl)methyl]-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-05-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-10-(3-thiazolidinylmethyl)-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-06-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-10-(4-morpholinylmethyl)-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-07-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-10-(4-thiomorpholinylmethyl)-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-55-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(2-pyridinylmethyl)oxime], (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-56-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(2-methyl-2H-tetrazol-5-yl)methyl]oxime], (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-53-6 CAPLUS
CN Acetic acid, [[[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-, 2-[2-(2-methoxyethoxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 511531-54-7 CAPLUS
CN Acetamide, 2-[[[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-1-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 511531-57-0 CAPLUS
CN 2,4-Thiazolidinedione, 3-[2-[[[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



IT **308244-21-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(radicicols as antirheumatic agents and promoters of Fas-induced apoptosis)
RN 308244-21-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **511531-62-7P 511531-63-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(radicicols as antirheumatic agents and promoters of Fas-induced apoptosis)
RN 511531-62-7 CAPLUS
CN Benzoic acid, 4-bromo-, (1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 511531-63-8 CAPLUS
CN Benzoic acid, 4-bromo-, (1aR,2Z,4E,6E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9-(methoxymethoxy)-14-methyl-12-oxo-6-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]imino]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)

L59 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:197762 CAPLUS
DOCUMENT NUMBER: 138:217883
TITLE: Method for measuring binding activity to heat shock protein 90 family protein
INVENTOR(S): Soga, Shiro; Akinaga, Shiro; Sugimoto, Seiji
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003075449	A2	20030312	JP 2001-269355	20010905
PRIORITY APPLN. INFO.:			JP 2001-269355	20010905

AB A method is provided for measuring the binding activity of a test substance to a heat shock protein 90 family protein. The method comprises a step for contacting either of a biotinylated radicicol derivative or heat shock protein 90 family protein immobilized on a solid phase with a test substance and the other of the biotinylated radicicol derivative or heat shock protein 90 family protein, and competitively binding the test substance and the biotinylated radicicol derivative with the heat shock protein 90 family protein, and a step for quantitating the binding complex of the heat shock protein 90 family protein and the biotinylated radicicol derivative formed in the step of the competitive binding. Moreover, these two steps are performed on the identical solid phase.

IT **184537-60-8 207745-73-1 308244-21-5 501124-40-9**
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(method for measuring binding activity to heat shock protein 90 family protein)
RN 184537-60-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-5-(formyloxy)-3,4,5,6-tetrahydro-14,16-dihydroxy-3-methyl-, 11-(O-methyloxime), (3R,5R,6S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-73-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-,

L59 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



L59 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6Z,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 308244-21-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 501124-40-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-oxime, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



Applicants

L59 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:157779 CAPLUS
DOCUMENT NUMBER: 136:216593
TITLE: Preparation of therapeutic macrocyclic natural product derivatives
INVENTOR(S): Danishefsky, Samuel J.; Garbaccio, Robert M.; Baeschlin, Daniel K.; Stachel, Shawn J.; Solit, David; Shtil, Alexander; Rosen, Neal
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016369	A2	20020228	WO 2001-US26577	20010824
WO 2002016369	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001086768	A5	20020304	AU 2001-86768	20010824
US 2002091151	A1	20020711	US 2001-938754	20010824
EP 1315732	A2	20030604	EP 2001-966236	20010824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2000-228277P P 20000825
US 2001-304553P P 20010711
US 2001-938754 A 20010824
WO 2001-US26577 W 20010824

OTHER SOURCE(S): MARPAT 136:216593
GI

L59 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II



AB The title compds. I (R1, R3 = H, halo, aliphatic, aryl, heteroaliph., heteroacyl, alkylacyl, alkylheteroaryl, NRA, RA = H, protecting group, aliphatic, heteroaliph., aryl, heteroacyl, alkylaryl, alkylheteroaryl; R2, R4 = H, halo, cyano, ORB, SRB, NRB2, CORB, NRBCORB, CO2RB, CONRB2, OCO2RB, aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, RB = H, protecting group, aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl; Z = O, S, NRE, RE = H, protecting group, aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, etc.; X = O, S, NRG, RG = H alkyl; A-B = Q, Y = CH2, O, NH, substituted N; CHR5CHR6, CR5:CR6, R5, R6 = H, halo, cyano, aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, etc.; D-E = CHR8-CH9, CR8:CR9, R8, R9 = H, alkyl; G-J = CHR10-CH11, CR10=C11, C10, C11 = H, alkyl; KL = CO, C=S, Et, C=CH, CHNH2, etc.) and their derivs. were prepared as therapeutic agents. I represents compds. selected from a group consisting of radicicol, monocillin and their analogs. Thus, radicicol (II, Y1 = O) and cyclopropyl-radicicol (II, Y1 = CH2) were prepared in a multistep synthesis starting from Me (R)-3-hydroxybutyrate. II and its derivs. were tested for antitumor activity against MCF7 and BT474 cells.

IT **75207-13-5P**, Monocillin I **401584-89-2P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of therapeutic macrocyclic natural product derivs.)

RN 75207-13-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aR,2Z,4E,14R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L59 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



P

RN 401584-89-2 CAPLUS
CN Benzo[c]cycloprop[k]oxacyclotetradecin-6,12(1H,7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aS,2Z,4E,14R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



IT **401584-88-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of therapeutic macrocyclic natural product derivs.)

RN 401584-88-1 CAPLUS
CN Benzo[c]cycloprop[k]oxacyclotetradecin-6,12(1H,7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aS,2Z,4E,14R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



IT **378749-98-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of therapeutic macrocyclic natural product derivs.)

RN 378749-98-5 CAPLUS
CN Spiro[1,3-dithiane-2,6'-[6H]oxireno[e][2]benzoxacyclotetradecin]-12'(7'H)-

L59 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
one, 11'-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-9'-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1'a,14',15',15'a-tetrahydro-14'-methyl-, (1'aR,2'Z,4'E,14'R,15'aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.

PAGE 1-B



PAGE 2-A



t-Bu

L59 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-B



L59 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:910815 CAPLUS
DOCUMENT NUMBER: 134:231560
TITLE: Radicicol binds and inhibits mammalian ATP citrate lyase
AUTHOR(S): Ki, Se Won; Ishigami, Ken; Kitahara, Takeshi; Kanahara, Koji; Yoshida, Minoru; Horinouchi, Sueharu
CORPORATE SOURCE: Department of Biotechnology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan
SOURCE: Journal of Biological Chemistry (2000), 275(50), 39231-39236
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Six different biotinylated radicicol derivs. were synthesized as affinity probes for identification of cellular radicicol-binding proteins. Derivs. biotinylated at the C-17 (BR-1) and C-11 (BR-6) positions retained the activity of morphol. reversion in v-src-transformed 3Y1 fibroblasts. Two radicicol-binding proteins, 120 and 90-kDa in size, were detected in HeLa cell exts. by employing BR-1 and BR-6, resp. The 90-kDa protein bound to BR-6 was identified to be Hsp90 by immunoblotting. The 120-kDa protein bound to BR-1 was purified from rabbit reticulocyte lysate, and its internal amino acid sequence was identical to that of human and rat ATP citrate lyase. The identity of the 120-kDa protein as ATP citrate lyase was confirmed by immunoblotting. Interaction between BR-1 and ATP citrate lyase was blocked by radicicol but not by herbimycin A that interacts with Hsp90. These results suggest that radicicol binds the two proteins through different mol. portions of its structure. BR-1-bound ATP citrate lyase isolated from rabbit reticulocyte lysate showed no enzymic activity. The activity of rat liver ATP citrate lyase was inhibited by radicicol and BR-1 but not by BR-6. Kinetic anal. demonstrated that radicicol was a non-competitive inhibitor of ATP citrate lyase with Ki values for citrate and ATP of 13 and 7 μM, resp.

IT **88929-18-4P 329967-56-8P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(protein binding and induction of morphol. reversion in v-src-transformed cells by radicicol and derivs.)

RN 88929-18-4 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, (1aR,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L59 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 329967-56-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6,7,8,9,10-octahydro-5,14,16-trihydroxy-3-methyl-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **329967-55-7P 329967-57-9P 329967-58-0P**
329967-59-1P 329967-60-4P 329967-62-6P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(protein binding and induction of morphol. reversion in v-src-transformed cells by radicicol and derivs.)

RN 329967-55-7 CAPLUS
CN Hexadecanoic acid, 16-hydroxy-, (1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 329967-57-9 CAPLUS
CN Hexanoic acid, 6-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]amino]-, (1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 329967-58-0 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[6-[[3-[[(1aR,14R,15aR)-8-chloro-1a,3,4,5,6,7,12,14,15,15a-decahydro-11-hydroxy-14-methyl-6,12-dioxo-2H-oxireno[e][2]benzoxacyclotetradecin-9-yl]oxy]propyl]amino]-6-oxohexyl]amino]-6-oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L59 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 329967-59-1 CAPLUS
CN Hexanoic acid, 6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-, [(1aR,14R,15aR)-8-chloro-1a,2,3,4,5,7,12,14,15,15a-decahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 329967-60-4 CAPLUS
CN Hexanoic acid, 6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-

L59 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

d]imidazol-4-yl]-1-oxopentyl]amino]-, [(3R,5S)-13-chloro-1,3,4,5,6,7,8,9,10,12-decahydro-5,14,16-trihydroxy-3-methyl-1-oxo-11H-2-benzoxacyclotetradecin-11-ylidene]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 329967-62-6 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[6-[[3-[[[(1aR,2Z,4E,14R,15aR)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]propyl]amino]-6-oxohexyl]amino]-6-oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



L59 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-B



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 7 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:664244 CAPLUS
DOCUMENT NUMBER: 134:261
TITLE: Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex
AUTHOR(S): Shiotsu, Yukimasa; Neckers, Leonard M.; Wortman, Ivo; An, Won G.; Schulte, Theodor W.; Soga, Shiro; Murakata, Chikara; Tamaoki, Tatsuya; Akinaga, Shiro
CORPORATE SOURCE: Kyowa Hakko Kogyo, Pharmaceutical Laboratories, Shizuoka, Japan
SOURCE: Blood (2000), 96(6), 2284-2291
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Chronic myelogenous leukemia (CML) is a clonal disorder of a pluripotent hematopoietic stem cells characterized by a chimeric bcr-abl gene giving rise to a p210Bcr-Abl protein with dysregulated tyrosine kinase activity. Radicicol, a macrocyclic antifungal antibiotic, binds to the N-terminal of heat shock protein 90 (Hsp90) and destabilizes Hsp90-associated proteins such as Raf-1. This study investigated the effect of radicicol, novel oxime derivs. of radicicol (KF25706 and KF58333), and herbimycin A (HA), a benzoquinoid ansamycin antibiotic, on the growth and differentiation of human K562 CML cells. Although KF25706 and KF58333 induced the expression of glycophorin A in K562 cells, radicicol and HA caused erythroid differentiation transiently. Cell cycle anal. showed that G1 phase accumulation was observed in K562 cells treated with KF58333. KF58333 treatment depleted p210Bcr-Abl, Raf-1, and cellular tyrosine phosphorylated proteins in K562 cells, whereas radicicol and HA showed transient depletion of these proteins. KF58333 also down-regulated the level of cell cycle-dependent kinases 4 and 6 and up-regulated cell cycle-dependent kinase inhibitor p27Kipl protein without an effect on the level of Erk and Hsp90 proteins. Immunopptn. anal. showed that p210Bcr-Abl formed multiple complexes with Hsp90, some containing p23 and others Hsp70; KF58333 treatment dissociated p210Bcr-Abl from Hsp90/p23 chaperone complexes. Furthermore, KF58333 induced apoptosis in K562 cells and administration of KF58333 prolonged the survival time of SCID mice inoculated with K562 cells. These results suggest that KF58333 may have therapeutic potential for the treatment of CML that involves abnormal cellular proliferation induced by p210Bcr-Abl.

IT **184537-25-5**, KF 25706 **308244-21-5**, KF 58333
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel oxime derivs. of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex)

RN 184537-25-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-oxime, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

L59 ANSWER 7 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 308244-21-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 8 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:605981 CAPLUS
DOCUMENT NUMBER: 133:321738
TITLE: Efficient Asymmetric Synthesis of Radicicol Dimethyl Ether: A Novel Application of Ring-Forming Olefin Metathesis
AUTHOR(S): Garbaccio, Robert M.; Danishefsky, Samuel J.
CORPORATE SOURCE: Laboratory for Bioorganic Chemistry, Sloan-Kettering Institute for Cancer Research, New York, NY, 10021, USA
SOURCE: Organic Letters (2000), 2(20), 3127-3129
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:321738
GI



I

AB A concise, stereospecific synthesis of radicicol di-Me ether (I) is presented. The strategy relies on a convergent three-stage assembly of the 14-membered lactone which has, as a key transformation, a novel ring-forming metathesis reaction utilizing a vinyl epoxide.

IT **303044-45-3P 303082-22-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(asym. synthesis of radicicol di-Me ether via ring-forming metathesis)

RN 303044-45-3 CAPLUS
CN Spiro[1,3-dithiane-2,6'-[6H]oxireno[e][2]benzoxacyclotetradecin]-12'(7'H)-one, 1'a,14',15',15'a-tetrahydro-9',11'-dimethoxy-14'-methyl-, (1'aR,2'Z,4'E,14'R,15'aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.

L59 ANSWER 8 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 303082-22-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dimethoxy-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.

L59 ANSWER 9 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **75207-16-8P**, Radicicol Dimethyl Ether
RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of radicicol di-Me ether via ring-forming metathesis)
RN 75207-16-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dimethoxy-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 9 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 88929-18-4 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, (1aR,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 9 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:456875 CAPLUS
DOCUMENT NUMBER: 133:94513
TITLE: Compounds which affect mRNA stability and uses therefor
INVENTOR(S): Kastelic, Tania; Cheneval, Dominique; Ruetz, Stephan
PATENT ASSIGNEE(S): Novation Pharmaceuticals Inc., Can.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038674	A1	20000706	WO 1999-CA1234	19991223
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356622	AA	20000706	CA 1999-2356622	19991223
EP 1140069	A1	20011010	EP 1999-962012	19991223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6635671	B1	20031021	US 2001-869078	20010815

PRIORITY APPLN. INFO.: GB 1998-28707 A 19981224
GB 1998-28710 A 19981224
WO 1999-CA1234 W 19991223

OTHER SOURCE(S): MARPAT 133:94513

AB Compds. which induce degradation of mRNA which contains 1 or more mRNA instability sequences are provided for use as pharmaceuticals, e.g. for use in the prophylaxis or treatment of diseases and medical conditions in general having an etiol. associated with the increased or prolonged stability of mRNAs, and which on prolonged or inappropriate expression typically give rise to undesirable effects, e.g., cancer cell growth or an unwanted inflammatory response. Thus, tablets contained a radicicol analog 500.0, lactose 500.0, potato starch 352.0, gelatin 8.0, talc 60.0, Mg stearate 10.0, EtOH qs and SiO2 20.0 g/10,000 tablets.

IT **75207-12-4 88929-18-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. inducing mRNA degradation for pharmaceuticals)
RN 75207-12-4 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, (1aS,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:708754 CAPLUS
DOCUMENT NUMBER: 131:322485
TITLE: Preparation of radicicol derivatives as tyrosine kinase inhibitors
INVENTOR(S): Ino, Yoji; Amishiro, Nobuyoshi; Miyata, Mayumi; Agatsuma, Tsutomu; Murakata, Chikara; Akinaga, Shiro; Soga, Shiro; Shiotsu, Yukimasa
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955689	A1	19991104	WO 1999-JP2138	19990422
W: AU, BG, BR, CA, CN, CZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9935344	A1	19991116	AU 1999-35344	19990422

PRIORITY APPLN. INFO.: JP 1998-114941 19980424
WO 1999-JP2138 19990422

OTHER SOURCE(S): MARPAT 131:322485
GI



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1, R2 = H, alkanoyl, etc.; Y = (un)substituted alkylene; R3 = NR5R6, NR7COR8, NR9R10, NR11COR12, substituted alkoxy, (un)substituted alkenyloxy; R5 = H, (un)substituted lower alkyl, etc.; R6 = substituted alkyl, etc.; R7 = H, (un)substituted alkyl, etc.; R8 = substituted alkyl, substituted alkoxy; R9, R10 = H, (un)substituted alkyl, etc.; R11 = (un)substituted alkyl, etc.; R12 = lower alkyl, lower alkoxy, X = halo; or XR4 = single bond; also, R4 = H, alkanoyl, etc.] or their salts, having tyrosine kinase inhibitory activity and therefore useful as antitumors and immunosuppressants, are prepared. Thus, radicicol was treated with II (also prepared) in pyridine at room temperature for 45 h to give a mixture of syn- and anti-III. IV (also prepared) had an IC50 of 0.02 μM against tyrosine kinase inside SR-3Y1 cells.

IT **248274-54-6P 248274-55-7P 248274-56-8P**
248274-57-9P 248274-58-0P 248274-59-1P
248274-60-4P 248274-61-5P 248274-62-6P
248274-63-7P 248274-64-8P 248274-65-9P
248274-66-0P 248274-67-1P 248274-68-2P
248274-69-3P 248274-70-6P 248274-71-7P
248274-72-8P 248274-73-9P 248274-74-0P
248274-75-1P 248274-76-2P 248274-77-3P
248274-78-4P 248274-79-5P 248274-80-8P
248274-81-9P 248274-82-0P 248274-83-1P
248274-84-2P 248274-85-3P 248274-86-4P
248274-88-6P 248274-89-7P 248274-90-0P
248274-91-1P

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of radicicol derivs. as tyrosine kinase inhibitors)
RN 248274-54-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[3-[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]propyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-55-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[3-(cyclohexylamino)propyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-56-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[4-[(4-pyridinylmethyl)amino]butyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-59-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-hydroxy-3-[(4-pyridinylmethyl)amino]propyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-60-4 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-57-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[4-[methyl(4-pyridinylmethyl)amino]butyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-58-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[3-[(1H-pyrrol-2-ylmethyl)amino]propyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 248274-61-5 CAPLUS
CN Urea, N-[4-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]butyl]-N'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-62-6 CAPLUS
CN Carbamic acid, [2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-63-7 CAPLUS
CN Carbamic acid, [2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]ethyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-64-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]oxime], (1aS,2Z,4E,14R,15aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-65-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-[3-(6-methyl-2-pyridinyl)propoxy]ethyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-66-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(2E)-3-phenyl-2-propenyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-67-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(1-methyl-1H-pyrrol-2-yl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-68-2 CAPLUS

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(1-methyl-1H-pyrazol-4-yl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-69-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(1-methyl-1H-imidazol-4-yl)methyl]oxime], (1aS,2Z,4E,14R,15aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-70-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(1-methyl-1H-imidazol-2-yl)methyl]oxime], (1aS,2Z,4E,14R,15aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-71-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(2-oxazolylmethyl)oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-72-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(3,5-dimethyl-4-isoxazolyl)methyl]oxime], (1aS,2Z,4E,14R,15aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 248274-73-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(4-methyl-5-thiazolyl)ethyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-74-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[[2-(3-pyridinyl)-5-thiazolyl]methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-75-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(1,2,4-oxadiazol-3-ylmethyl)oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-78-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(pyrazinylmethyl)oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-79-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(1,4-dihydro-6-methoxy-4-oxo-5-pyrimidinyl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-76-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(1-methyl-1H-tetrazol-5-yl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-77-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(2-methyl-2H-tetrazol-5-yl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-80-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-3-oxazolidinyl)ethyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-81-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-piperidinyl)ethyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-82-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(hexahydro-2-oxo-1H-azepin-1-yl)ethyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-83-1 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,7,12,14,15,15a-hexahydro-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-86-4 CAPLUS
CN 2,4-Thiazolidinedione, 3-[2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,7,12,14,15,15a-hexahydro-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 248274-88-6 CAPLUS
CN 2,4-Thiazolidinedione, 3-[2-[[(Z)-[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-84-2 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[2-[[(E)-[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 248274-85-3 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[2-[[(Z)-[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-89-7 CAPLUS
CN 2,4-Thiazolidinedione, 3-[2-[[(E)-[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 248274-90-0 CAPLUS
CN 2,4-Imidazolidinedione, 3-[2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,7,12,14,15,15a-hexahydro-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 248274-91-1 CAPLUS
CN 2,4-Imidazolidinedione, 3-[2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]ethyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



IT **184758-79-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of radicicol derivs. as tyrosine kinase inhibitors)
RN 184758-79-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **248275-29-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of radicicol derivs. as tyrosine kinase inhibitors)
RN 248275-29-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, 6-[O-(2-hydroxyethyl)oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:408030 CAPLUS
DOCUMENT NUMBER: 131:193905
TITLE: KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules
AUTHOR(S): Soga, Shiro; Neckers, Leonard M.; Schulte, Theodor W.; Shiotsu, Yukimasa; Akasaka, Kazuhito; Narumi, Hiroaki; Agatsuma, Tsutomu; Ikuina, Yoji; Murakata, Chikara; Tamaoki, Tatsuya; Akinaga, Shiro
CORPORATE SOURCE: Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, 411-8731, Japan
SOURCE: Cancer Research (1999), 59(12), 2931-2938
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: AACR Subscription Office
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Radicicol, a macrocyclic antifungal antibiotic, has been shown to bind to the heat shock protein 90 (Hsp90) chaperone, interfering with its function. Hsp90 family chaperones have been shown to associate with several signaling mols. and play an essential role in signal transduction, which is important for tumor cell growth. Because radicicol lacks antitumor activity in vivo in exptl. animal models, we examined the antitumor activity of a novel radicicol oxime derivative, radicicol 6-oxime (KF25706), on human tumor cell growth both in vitro and in vivo. KF25706 showed potent antiproliferative activities against various human tumor cell lines in vitro and inhibited v-src- and K-ras-activated signaling as well as radicicol. In addition, Hsp90 family chaperone-associated proteins, such as p185erbB2, Raf-1, cyclin-dependent kinase 4, and mutant p53, were depleted by KF25706 at a dose comparable to that required for antiproliferative activity. KF25706 was also shown to compete with geldanamycin for binding to Hsp90. KF29163, which is an inactive derivative of radicicol, was less potent both in p185erbB2 depletion and Hsp90 binding. More importantly, KF25706 showed significant growth-inhibitory activity against human breast carcinoma MX-1 cells transplanted into nude mice at a dose of 100 mg/kg twice daily for five consecutive i.v. injections. KF25706 was also shown to possess antitumor activity against human breast carcinoma MCF-7, colon carcinoma DLD-1, and vulval carcinoma A431 cell lines in vivo in an animal model. Finally, we confirmed the depletion of Hsp90-associated signaling mols. (Raf-1 and cyclin-dependent kinase 4) with ex vivo Western blotting anal. using MX-1 xenografts. In agreement with in vivo antitumor activity, KF25706 depleted Hsp90-associated mols. in vivo, whereas KF29163 and radicicol did not show this activity in vivo. Taken together, these results suggest that antitumor activity of KF25706 may be mediated, at least in part, by binding to Hsp90 family proteins and destabilization of Hsp90-associated signaling mols.
IT **184537-25-5**, KF 25706
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KF25706, oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling mols.)
RN 184537-25-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-oxime, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **184537-60-8**, KF 29163
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(comparison with; KF25706, oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling mols.)
RN 184537-60-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-5-(formyloxy)-3,4,5,6-tetrahydro-14,16-dihydroxy-3-methyl-, 11-(O-methyloxime), (3R,5R,6S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 12 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:722054 CAPLUS
DOCUMENT NUMBER: 130:63441
TITLE: Antifungal metabolites (monorden, monocillin IV, and cerebrosides) from Humicola fuscoatra traaen NRRL 22980, a mycoparasite of Aspergillus flavus sclerotia
AUTHOR(S): Wicklow, Donald T.; Joshi, Biren K.; Gamble, William R.; Gloer, James B.; Dowd, Patrick F.
CORPORATE SOURCE: Bioactive Agents Research, U.S. Department of Agriculture, Peoria, IL, 61604, USA
SOURCE: Applied and Environmental Microbiology (1998), 64(11), 4482-4484
CODEN: AEMIDF; ISSN: 0099-2240
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The mycoparasite Humicola fuscoatra NRRL 22980 was isolated from a sclerotium of Aspergillus flavus that had been buried in a cornfield near Tifton, Ga. When grown on autoclaved rice, this fungus produced the antifungal metabolites monorden, monocillin IV, and a new monorden analog. Each metabolite produced a clear zone of inhibition surrounding paper assay disks on agar plates seeded with conidia of A.flavus. Monorden was twice as inhibitory to A. flavus mycelium extension (MIC > 28 μg/mL) as monocillin IV (MIC > 56 μg/mL). Cerebrosides C and D, metabolites known to potentiate the activity of cell wall-active antibiotics, were separated from the Et acetate extract but were not inhibitory to A. flavas when tested as pure compds. This is the first report of natural products from H. fitscoatra.

IT **75207-14-6**, Monocillin IV
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(antifungal metabolites of Humicola fuscoatra as mycoparasite of Aspergillus flavus sclerotia)

RN 75207-14-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,7,8,9,10-hexahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:650399 CAPLUS
DOCUMENT NUMBER: 129:335744
TITLE: Preventive agents for coronary artery restenosis
INVENTOR(S): Ikeda, Masahiro; Shimada, Yoko
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10265381	A2	19981006	JP 1997-69340	19970324

PRIORITY APPLN. INFO.: JP 1997-69340 19970324
OTHER SOURCE(S): MARPAT 129:335744
GI



I

AB Preventive agents for coronary artery restenosis after percutaneous transluminal coronary angioplasty contain radicicol (I) or related compds. such as dipalmitoyl radicicol as active ingredient. Capsules were formulated containing dipalmitoyl radicicol 100, lactose 168.3, corn starch 70 and magnesium stearate 1.7 mg.

IT **194085-05-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preventive agents for coronary artery restenosis)

RN 194085-05-7 CAPLUS
CN Hexadecanoic acid, (1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:293491 CAPLUS
DOCUMENT NUMBER: 129:16017
TITLE: Preparation of radicicol derivatives as tyrosine kinase inhibitors
INVENTOR(S): Ino, Yoji; Amishiro, Nobuyoshi; Miyata, Mayumi; Murakata, Chikara; Ogawa, Hacumi; Akiyama, Tadakazu; Akinaga, Shiro; Soga, Shiroh; Shiotsu, Yukimasa; et al.
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818780	A1	19980507	WO 1997-JP3874	19971024
W: AU, BG, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2241624	AA	19980507	CA 1997-2241624	19971024
AU 9747239	A1	19980522	AU 1997-47239	19971024
AU 727722	B2	20001221		
EP 889042	A1	19990107	EP 1997-909629	19971024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1211244	A	19990317	CN 1997-192375	19971024
NZ 331062	A	20000526	NZ 1997-331062	19971024
US 6316491	B1	20011113	US 1998-91752	19980624
NO 9802960	A	19980825	NO 1998-2960	19980625
US 6239168	B1	20010529	US 2000-513472	20000225
US 2001027208	A1	20011004	US 2001-791602	20010226
US 6635662	B2	20031021		
US 2004053990	A1	20040318	US 2003-629655	20030730

PRIORITY APPLN. INFO.: JP 1996-284439 A 19961025
JP 1997-3578 A 19970113
WO 1997-JP3874 W 19971024
US 1998-91752 A3 19980624
US 2000-513472 A3 20000225
US 2001-791602 A3 20010226

OTHER SOURCE(S): MARPAT 129:16017
GI

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB Radicicol derivs. I [R1, R2 =H, alkanoyl, alkenoyl, tert-butyldiphenylsilyl, tert-butyldimethylsilyl; R3 = Y-R5 (Y = (un)substituted alkylene; R5 = CONR6R7, etc.; R6 = H, OH, (un)substituted alkyl, etc.; R7 = OH, substituted lower alkyl, etc.), CO2R12; R12 = (un)substituted alkyl, etc.; X = halo; R4 = H, alkanoyl, etc.; or XR4 = single bond] or their pharmacol. acceptable salts are prepared Thus, radicicol was reacted with aminoxyacetic acid hemihydrochloride to give the intermediate II, which was reacted with piperidine in DMF containing HOBt and 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide to give the title compound I [R1 = R2 = H, R3 = piperidinocarbonylmethyl, R4-X = bond]. This had an IC50 of 0.37 μM in inhibiting the activity of tyrosine kinase inside cells.

IT **207745-06-0P 207745-07-1P 207745-08-2P**
207745-09-3P 207745-10-6P 207745-11-7P
207745-12-8P 207745-13-9P 207745-14-0P
207745-15-1P 207745-16-2P 207745-17-3P
207745-18-4P 207745-19-5P 207745-20-8P
207745-21-9P 207745-22-0P 207745-23-1P
207745-24-2P 207745-25-3P 207745-26-4P
207745-27-5P 207745-28-6P 207745-29-7P
207745-30-0P 207745-31-1P 207745-32-2P
207745-33-3P 207745-34-4P 207745-35-5P
207745-36-6P 207745-37-7P 207745-38-8P
207745-39-9P 207745-40-2P 207745-41-3P
207745-42-4P 207745-43-5P 207745-44-6P
207745-45-7P 207745-46-8P 207745-47-9P
207745-48-0P 207745-49-1P 207745-50-4P

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

207745-51-5P 207745-52-6P 207745-53-7P
207745-54-8P 207745-55-9P 207745-56-0P
207745-57-1P 207745-58-2P 207745-59-3P
207745-60-6P 207745-61-7P 207745-62-8P
207745-63-9P 207745-64-0P 207745-65-1P
207745-66-2P 207745-67-3P 207745-68-4P
207745-69-5P 207745-70-8P 207745-71-9P
207745-72-0P 207745-73-1P 207745-75-3P
207745-76-4P 207745-77-5P 207745-78-6P
207745-79-7P 207745-80-0P 207745-81-1P
308244-21-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of radicicol derivs. as tyrosine kinase inhibitors)

RN 207745-06-0 CAPLUS
CN Piperidine, 1-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-07-1 CAPLUS
CN Pyrrolidine, 1-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-08-2 CAPLUS
CN Morpholine, 4-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-09-3 CAPLUS
CN Piperazine, 1-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-10-6 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-11-7 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-12-8 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-13-9 CAPLUS
CN Glycine, N-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-14-0 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-15-1 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-, 2-[(phenylamino)carbonyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-16-2 CAPLUS
CN 1H-Azepine, 1-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]hexahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-17-3 CAPLUS
CN Piperidine, 1-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-18-4 CAPLUS
CN 4-Piperidinol, 1-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-19-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-20-8 CAPLUS
CN 4-Piperidinecarboxamide, 1-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-21-9 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-24-2 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-25-3 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-26-4 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
ylidene]amino]oxy]-N-decyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-22-0 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-(3-chloropropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-23-1 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
ylidene]amino]oxy]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-27-5 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-28-6 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-29-7 CAPLUS
CN Acetamide, 2-[[(Z)-[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 207745-30-0 CAPLUS
CN Acetamide, 2-[[(E)-[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Double bond geometry as shown.



RN 207745-31-1 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-32-2 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-cyclopentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-33-3 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-34-4 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-35-5 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-36-6 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-37-7 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-3-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-38-8 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-, 2,2-dimethylhydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-41-3 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-, 2-(2-pyridinyl)hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-42-4 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-1-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as desccibed by E or Z.



L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-39-9 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-, 1-(2-hydroxyethyl)hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-40-2 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-, 2-phenylhydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 207745-43-5 CAPLUS
CN Acetamide, 2-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-N-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-44-6 CAPLUS
CN Piperidine, 1-[8-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-1-oxooctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-45-7 CAPLUS
CN Piperidine, 1-[11-[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-1-oxoundecyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-46-8 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-, 3,6,9,12,15-pentaoxahexadec-1-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



RN 207745-47-9 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]-, 2-[2-(2-methoxyethoxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-48-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(phenylmethyl)oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-49-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(2-hydroxyphenyl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-50-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(3,5-dihydroxyphenyl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-51-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(3,4,5-trimethoxyphenyl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-52-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(3,5-diaminophenyl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-53-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-[4-(dimethylamino)phenyl]ethyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-54-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-55-9 CAPLUS
CN Benzenesulfonamide, 2-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-58-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(3-pyridinylmethyl)oxime], (1aS,2Z,4E,6Z,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 207745-59-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(4-pyridinylmethyl)oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-56-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(2-pyridinylmethyl)oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-57-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(3-pyridinylmethyl)oxime], (1aS,2Z,4E,6E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-60-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[3-(3-pyridinyl)propyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-61-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(3-hydroxy-2-pyridinyl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 207745-62-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[[3-(methoxymethoxy)-2-pyridinyl]methyl]oxime], (1aS,2Z,4E,14R,15aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-63-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]oxime], (1aS,2Z,4E,14R,15aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-64-0 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-[[[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-67-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[3-(1-piperidinyl)propyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-68-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[3-(4-hydroxy-1-piperidinyl)propyl]oxime], (1aS,2Z,4E,14R,15aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-69-5 CAPLUS

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-65-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(1-methyl-3-piperidinyl)methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-66-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(1-pyrrolidinyl)ethyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[4-(4-morpholinyl)butyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-70-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[3-(4-methyl-1-piperazinyl)propyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-71-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[4-(4-phenyl-1-piperazinyl)butyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-72-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[4-(4-thiomorpholinyl)butyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-73-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6Z,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-77-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-(1,3-dioxolan-2-yl)ethyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-78-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(ethoxycarbonyl)oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-75-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[3-(2-oxo-1-pyrrolidinyl)propyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-76-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[2-hydroxy-2-(1-pyrrolidinyl)ethyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 207745-79-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[(methylamino)carbonyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-80-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-(O-acetyloxime), (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-81-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-(O-phenyloxime), (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 308244-21-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(2-(2-oxo-1-pyrrolidinyl)ethyl]oxime], (1aR,2Z,4E,6E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **184537-27-7P 184537-55-1P 207745-82-2P**
207745-83-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of radicicol derivs. as tyrosine kinase inhibitors)
RN 184537-27-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, 6-oxime, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 207745-83-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, 6-[O-(ethoxycarbonyl)oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184537-55-1 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 207745-82-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, 6-[O-[[3-(methoxymethoxy)-2-pyridinyl]methyl]oxime], (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 15 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1997:664969 CAPLUS
DOCUMENT NUMBER:	127:328558
TITLE:	Fragmentation of some zearalenones by fast-atom bombardment mass spectrometry
AUTHOR(S):	Rodrigues Filho, Edson; Xie, Weiping; Mirocha, Chester J.; Hogge, Laurence R.
CORPORATE SOURCE:	Departamento de Quimica, Universidade Federal de Sao Carlos, Brazil
SOURCE:	Rapid Communications in Mass Spectrometry (1997), 11(14), 1515-1520 CODEN: RCMSEF; ISSN: 0951-4198
PUBLISHER:	Wiley
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB The pos.-ion fast-atom bombardment (FAB) mass spectra of 23 zearalenones derivs. have been obtained and structures for the ion fragments were proposed. Careful anal. of the FAB spectra obtained for these derivs., accurate mass measurements and MS/MS expts. for zearalenones, 3'-oxozearalenone and 7'-methanolzearalanone, have led to a proposed fragmentation scheme for this series of compds. This knowledge has been helpful in the identification of underivatized zearalenones from crude Fusarium rice culture exts.

IT **23791-62-0**
RL: ANT (Analyte); ANST (Analytical study)
(fragmentation of some zearalenones by fast-atom bombardment mass spectrometry)
RN 23791-62-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 16 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:526114 CAPLUS
DOCUMENT NUMBER: 127:176300
TITLE: Preparation of anticancer radisicol analogs
INVENTOR(S): Shibata, Tomoyuki; Oikawa, Tetsuo; Kobayashi, Tomoo; Shimazaki, Naomi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09202781	A2	19970805	JP 1996-10499	19960125

PRIORITY APPLN. INFO.: JP 1996-10499 19960125
OTHER SOURCE(S): MARPAT 127:176300
GI



I

AB Radisicol analogs I (R1, R2 = H, acyl; X = halo, OH, lower alkoxy), useful as anticancer agents (no data), are prepared Radisicol (5.50 g) was treated with 1N HCl in dioxane at room temperature for 4 h to give 319 mg I (R1 = R2 = H, X = Cl).
IT **194085-05-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of anticancer radisicol analogs)
RN 194085-05-7 CAPLUS
CN Hexadecanoic acid, (1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 16 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 194085-02-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6-tetrahydro-5,6,14,16-tetrahydroxy-3-methyl-, (3R,5S,7Z,9E)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 194085-03-5 CAPLUS
CN Hexadecanoic acid, 6,13-dichloro-3,4,5,6,11,12-hexahydro-5-hydroxy-3-methyl-1,11-dioxo-1H-2-benzoxacyclotetradecin-14,16-diyl ester, (3R,5S,7Z,9E)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L59 ANSWER 16 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **194084-99-6P 194085-01-3P 194085-02-4P 194085-03-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anticancer radisicol analogs)
RN 194084-99-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-3,4,5,6-tetrahydro-5,14,16-trihydroxy-3-methyl-, (3R,5S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 194085-01-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6-tetrahydro-5,14,16-trihydroxy-6-methoxy-3-methyl-, (3R,5S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:5942 CAPLUS
DOCUMENT NUMBER: 126:31222
TITLE: Preparation of radicicol derivatives as tyrosine kinase inhibitors
INVENTOR(S): Agatsuma, Tsutomu; Saitoh, Yutaka; Yamashita, Yoshinori; Mizukami, Tamio; Akinaga, Shiro; Gomi, Katsushige; Akasaka, Kazuhito; Takahashi, Isami
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9633989	A1	19961031	WO 1996-JP1158	19960426
W: AU, CA, CN, HU, JP, KR, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2218981	AA	19961031	CA 1996-2218981	19960426
AU 9662927	A1	19961118	AU 1996-62927	19960426
AU 700840	B2	19990114		
EP 823429	A1	19980211	EP 1996-912263	19960426
EP 823429	B1	20000712		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1189160	A	19980729	CN 1996-195001	19960426
AT 194610	E	20000715	AT 1996-912263	19960426
ES 2149468	T3	20001101	ES 1996-912263	19960426
NO 9704890	A	19971229	NO 1997-4890	19971023
US 5977165	A	19991102	US 1997-958285	19971027

PRIORITY APPLN. INFO.: JP 1995-102626 A 19950426
WO 1996-JP1158 W 19960426
OTHER SOURCE(S): MARPAT 126:31222
GI



I

AB Radicicol derivs. I [R1 and R2 may be the same or different and each = H, alkanoyl, alkenoyl or tert-butyldimethylsilyl; when X = halo, then Y = O or R4-O-N (R4 being H or (un)substituted lower alkyl) and R3 = H, alkanoyl, alkenoyl, etc.; when X is combined with R3 to form a single bond, Y = R4-O-N] and their pharmaceutically acceptable salts are prepared Thus, radicicol in DMF was treated with POCl3 at room temperature for 24 h to give I [R1 = R2 = H, R3 = CHO, X = Cl, Y = O]. I [R1 = R2 = H, XR3 =

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
bond, Y = O] (also prepd.) had an IC50 of 0.18 μM against tyrosine kinase. The derivs. have a tyrosine kinase inhibiting activity and thus have various pharmacol. activities such as antitumor, antibacterial and immunosuppressive effects. Pharmaceutical compns. contg. I are described.

IT **184537-26-6P 184537-55-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of radicicol derivs. as tyrosine kinase inhibitors)

RN 184537-26-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-(O-methyloxime), [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-55-1 CAPLUS
CN Acetic acid, [[[(1aS,2Z,4E,14R,15aS)-8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene]amino]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



IT **184537-18-6P 184537-19-7P 184537-20-0P**
184537-21-1P 184537-22-2P 184537-23-3P
184537-24-4P 184537-25-5P 184537-27-7P
184537-28-8P 184537-29-9P 184537-30-2P
184537-32-4P 184537-34-6P 184537-36-8P
184537-38-0P 184537-40-4P 184537-42-6P
184537-44-8P 184537-45-9P 184537-47-1P

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
184537-49-3P 184537-51-7P 184537-52-8P
184537-53-9P 184537-54-0P 184537-56-2P
184537-57-3P 184537-58-4P 184537-59-5P
184537-60-8P 184537-61-9P 184537-74-4P
184750-79-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of radicicol derivs. as tyrosine kinase inhibitors)

RN 184537-18-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-5-(formyloxy)-3,4,5,6-tetrahydro-14,16-dihydroxy-3-methyl-, (3R,5R,6S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 184537-19-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-3,4,5,6-tetrahydro-5,14,16-trihydroxy-3-methyl-, (3R,5R,6S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 184537-20-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6-bromo-13-chloro-3,4,5,6-tetrahydro-5,14,16-trihydroxy-3-methyl-, (3R,5R,6S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184537-21-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 5,5'-[sulfinylbis(oxy)]bis[6,13-dichloro-3,4,5,6-tetrahydro-14,16-dihydroxy-3-methyl-, [3R-[3R*,5R*(3'R*,5'R*,6'S*,7'Z,9'E),6S*,7Z,9E]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

RN 184537-22-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 5,14,16-tris(acetyloxy)-6,13-dichloro-3,4,5,6-tetrahydro-3-methyl-, [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 184537-23-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 14,16-bis(acetyloxy)-6,13-dichloro-5-(formyloxy)-3,4,5,6-tetrahydro-3-methyl-, [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 184537-24-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 5,5'-[sulfinylbis(oxy)]bis[14,16-bis(acetyloxy)-6,13-dichloro-3,4,5,6-tetrahydro-3-methyl-, [3R-[3R*,5R*(3'R*,5'R*,6'S*,7'Z,9'E),6S*,7Z,9E]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 184537-25-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-oxime, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-27-7 CAPLUS

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184537-30-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(3-azidopropyl)oxime], [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-32-4 CAPLUS
CN Hexadecanoic acid, 6,13-dichloro-5-(formyloxy)-3,4,5,6,11,12-hexahydro-3-methyl-1,11-dioxo-1H-2-benzoxacyclotetradecin-14,16-diyl ester, [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 184537-34-6 CAPLUS
CN Hexadecanoic acid, sulfinylbis[oxy(6,13-dichloro-3,4,5,6,11,12-hexahydro-3-methyl-1,11-dioxo-1H-2-benzoxacyclotetradecin-5,14,16-triyl)] ester, [3R-[3R*,5R*(3R*,5R*,6S*,7Z,9E),6S*,7Z,9E]]- (9CI) (CA INDEX NAME)

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, 6-oxime, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-28-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, 6-[O-(methoxymethyl)oxime], [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-29-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(methoxymethyl)oxime], [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A



RN 184537-36-8 CAPLUS
CN Hexadecanoic acid, 6,13-dichloro-3,4,5,6,11,12-hexahydro-5-hydroxy-3-methyl-1,11-dioxo-1H-2-benzoxacyclotetradecin-14,16-diyl ester, [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184537-38-0 CAPLUS
CN Hexadecanoic acid, 5-(acetyloxy)-6,13-dichloro-3,4,5,6,11,12-hexahydro-3-methyl-1,11-dioxo-1H-2-benzoxacyclotetradecin-14,16-diyl ester, [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 184537-40-4 CAPLUS
CN Hexadecanoic acid, 6-bromo-13-chloro-3,4,5,6,11,12-hexahydro-5-hydroxy-3-methyl-1,11-dioxo-1H-2-benzoxacyclotetradecin-14,16-diyl ester, [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184537-45-9 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, 6-[O-[6-(1,3-dihydro-2H-isoindol-2-yl)hexyl]oxime], [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-47-1 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-[6-(1,3-dihydro-2H-isoindol-2-yl)hexyl]oxime], [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184537-42-6 CAPLUS
CN Hexadecanoic acid, 5-(acetyloxy)-6-bromo-13-chloro-3,4,5,6,11,12-hexahydro-3-methyl-1,11-dioxo-1H-2-benzoxacyclotetradecin-14,16-diyl ester, [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 184537-44-8 CAPLUS
CN Hexadecanoic acid, 6-bromo-13-chloro-3,4,5,6,11,12-hexahydro-3-methyl-1,11-dioxo-1H-2-benzoxacyclotetradecin-5,14,16-triyl ester, [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184537-49-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(6-azidohexyl)oxime], [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-51-7 CAPLUS
CN Hexanoic acid, 6-[[(8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene)amino]oxy]-, 1,1-dimethylethyl ester, [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-52-8 CAPLUS
CN Hexanoic acid, 6-[[(8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene)amino]oxy]-, 2-(trimethylsilyl)ethyl ester, [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-53-9 CAPLUS
CN Carbamic acid, [6-[[(8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene)amino]oxy]hexyl]-, 2-propenyl ester, [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-54-0 CAPLUS
CN Hexanoic acid, 6-[[(8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene)amino]oxy]-, [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 184537-56-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, 6-[O-(3-hydroxypropyl)oxime], [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-57-3 CAPLUS
CN Hexadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-6-(methoxyimino)-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester, [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-58-4 CAPLUS

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-3,4,5,6-tetrahydro-5,14,16-trihydroxy-3-methyl-, 11-(O-methyloxime), [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-59-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6-bromo-13-chloro-3,4,5,6-tetrahydro-5,14,16-trihydroxy-3-methyl-, 11-(O-methyloxime), [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-60-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 6,13-dichloro-5-(formyloxy)-3,4,5,6-tetrahydro-14,16-dihydroxy-3-methyl-, 11-(O-methyloxime), (3R,5R,6S,7Z,9E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-61-9 CAPLUS
CN Acetamide, 2-[[(6,13-dichloro-1,3,4,5,6,12-hexahydro-5,14,16-trihydroxy-3-

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methyl-1-oxo-11H-2-benzoxacyclotetradecin-11-ylidene)amino]oxy]-N,N-dimethyl-, [3R-(3R*,5R*,6S*,7Z,9E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184537-74-4 CAPLUS
CN Acetamide, 2-[[(8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene)amino]oxy]-N,N-dimethyl-, [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 184758-79-0 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, (1aS,2Z,4E,14R,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **184537-65-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of radicicol derivs. as tyrosine kinase inhibitors)
RN 184537-65-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[[[(8-chloro-1a,7,12,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-12-oxo-6H-oxireno[e][2]benzoxacyclotetradecin-6-ylidene)amino]oxy]acetyl]oxy]-, [1aS-(1aR*,2Z,4E,14S*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



L59 ANSWER 18 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:293862 CAPLUS
DOCUMENT NUMBER: 122:81004
TITLE: Preparation of benzooxacyclotetradecendiones as cytokine release inhibitors.
INVENTOR(S): Dreyfuss, Michael Morris; Leutwiler, Albert; MacKenzie, Andrew Roland; Schnyder, Joerg; Traber, Rene Paul; Mattes, Henri
PATENT ASSIGNEE(S): Sandoz Ltd., Switz.; Sandoz-Patent-G.m.b.H.; Sandoz-Erfindungen Verwaltungsgesellschaft m.p.H.
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 606044	A1	19940713	EP 1993-810835	19931129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2110553	AA	19940605	CA 1993-2110553	19931202
FI 9305409	A	19940605	FI 1993-5409	19931202
NO 9304372	A	19940606	NO 1993-4372	19931202
AU 9352112	A1	19940616	AU 1993-52112	19931202
HU 65910	A2	19940728	HU 1993-3444	19931203
JP 06228122	A2	19940816	JP 1993-303866	19931203
CN 1095417	A	19941123	CN 1993-120777	19931203
ZA 9309088	A	19950605	ZA 1993-9088	19931203

PRIORITY APPLN. INFO.: GB 1992-25396 19921204
OTHER SOURCE(S): MARPAT 122:81004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. (I; R4, R6, R7, R8 = H, OH, alkoxy, alkylcarbonyloxy; R5 = OH, alkoxy, alkylcarbonyloxy; 1 of X1X2, X4X5 = CHR7CHR8, the other = cis- or trans-CR7CR8; X3 = CH(OH), CO; X6X7 = CH2CH2 or cis- or trans-CH:CH; starred center, X1, X2, X4, X5 may have R- or S-configurations), with provisos, were prepared I are cytokine release inhibitors and IL-1 antagonists for treating inflammatory states and diseases such as rheumatoid arthritis, osteoarthritis, septic shock, psoriasis, atherosclerosis, inflammatory bowel disease, Crohn's disease and asthma. Thus, 4-trimethylsilyloxyhex-1-yne (preparation given) in THF at -78° was treated with BuLi and then with pent-1-en-5-one (preparation given) to give 72% 2-trimethylsilyloxy-7-hydroxyundeca-4-yn-10-ene. This was hydrogenated in pyridine over 10% Pd/BaSO4 to give 2-trimethylsilyloxy-7-hydroxyundeca-cis-4,10-diene. This in CH2Cl2 was treated with diisopropylethylamine and then with 1-chloromethyl-2-methylglycol to give 2-trimethylsilyloxy-7-[(2-methoxy)ethoxy]methoxyundeca-cis-4,10-diene. The latter was converted to title compound II in several steps. Preferred title compound III was prepared by fermentation of NRRL 18919. Title compds.

L59 ANSWER 18 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
inhibited carrageenan-induced paw edema in rats with IC50 = 0.1-1 mg/kg.
IT **160191-50-4**, 9-O-Methylradicicol
RL: RCT (Reactant); RACT (Reactant or reagent)
(cytokine release inhibiting activity of)
RN 160191-50-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-11-hydroxy-9-methoxy-14-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L59 ANSWER 19 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:472925 CAPLUS
DOCUMENT NUMBER: 121:72925
TITLE: Effect of fungal natural products in an Agrobacteirum tumefaciens potato disk assay
AUTHOR(S): Bryant, Frank O.; Cutler, Horace G.; Parker, Stephen R.; Jacyno, John M.
CORPORATE SOURCE: Russell Res. Cent., USDA, Athens, GA, 30613, USA
SOURCE: Journal of Natural Products (1994), 57(5), 640-3
CODEN: JNPRDF; ISSN: 0163-3864
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An Agrobacterium tumefaciens potato disk assay was used to screen certain natural products (25 µg/disk) from fungi for crown gall tumor/antitumor induction. Monorden (-75.0%), cladosporin (-79.0%), monocillin IV (-79.6%), duclauxin (-96.0%), diplodiol (-96.3%), and chaetoglobosin K (-99.0%) displayed concentration-dependent responses at 5, 10, 25, and 50 µg/disk. These natural products were not antimicrobial as determined by sensitivity tests using fungi and bacteria, inclusive of A. tumefaciens.
IT **75207-14-6**, Monocillin IV
RL: ANST (Analytical study)
(antitumor response of, Agrobacterium tumefaciens potato disk assay for)
RN 75207-14-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,7,8,9,10-hexahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 20 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:298262 CAPLUS
DOCUMENT NUMBER: 120:298262
TITLE: Convergent stereospecific total synthesis of monocillin and monorden (or radicicol)
AUTHOR(S): Lett, Robert; Lampilas, Maxime; Tichkowsky, Isabelle
CORPORATE SOURCE: ROUSSEL UCLAF, Romainville, 93230, Fr.
SOURCE: Recent Prog. Chem. Synth. Antibiot. Relat. Microb. Prod. (1993), 99-120. Editor(s): Lukacs, Gabor. Springer: Berlin, Germany.
CODEN: 59POA7
DOCUMENT TYPE: Conference; General Review
LANGUAGE: English
AB Review with 79 refs. The isolation and the biol. properties of monorden (or radicicol) and monocillin I are briefly reviewed. The first total syntheses of these antifungal resorcylic 14-membered macrolides have been achieved by a convergent stereospecific route, in enantiomerically pure form, and are discussed herein. The flexibility of the scheme gives also a good access to unnatural macrolides of that class.
IT **75207-13-5P**, Monocillin I
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of)
RN 75207-13-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aR,2Z,4E,14R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L59 ANSWER 21 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:193998 CAPLUS
DOCUMENT NUMBER: 116:193998
TITLE: Convergent stereospecific total synthesis of monocillin I and monorden (or radicicol)
AUTHOR(S): Lampilas, Maxime; Lett, Robert
CORPORATE SOURCE: Roussel Uclaf, Romainville, 93230, Fr.
SOURCE: Tetrahedron Letters (1992), 33(6), 777-80
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The first total syntheses of the title compds. I (R = H, Cl) was achieved by a convergent stereospecific route. Me3CSiMe2 phenol ethers were found to be suitable for the entire reaction sequence and were removed in the ultimate step under mild conditions (aqueous borax/THF/methanol), providing I
in good yields, with no degradation
IT **140480-16-6P 140480-17-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and desilylation of)
RN 140480-16-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 21 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 140480-17-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 7-chloro-11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-9-hydroxy-14-methyl-, [1aR-(1aR*,2Z,4E,14R*,15aR*)]- (9CI) (CA INDEX NAME)



IT **140480-12-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and desilylation or chlorination of)
RN 140480-12-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **140480-14-4P 140480-15-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)

L59 ANSWER 21 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(prepn. of)
RN 140480-14-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-5-(hydroxymethyl)-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 140480-15-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 9,11-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1a,14,15,15a-tetrahydro-7-(hydroxymethyl)-14-methyl- (9CI) (CA INDEX NAME)



IT **75207-13-5P**, Monocillin I
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(stereospecific total synthesis of)
RN 75207-13-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aR,2Z,4E,14R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

L59 ANSWER 21 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:173844 CAPLUS
DOCUMENT NUMBER: 116:173844
TITLE: Convergent stereospecific total synthesis of monochiral monocillin I related macrolides
AUTHOR(S): Lampilas, Maxime; Lett, Robert
CORPORATE SOURCE: Roussel Uclaf, Romainville, 93230, Fr.
SOURCE: Tetrahedron Letters (1992), 33(6), 773-6
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The first total synthesis of the (7'S,8'S, 10'S)-enantiomer of Monocillin I di-Me ester I has been achieved by a convergent and stereospecific route involving the Pd-catalyzed coupling of chiral vinylstannane II with the appropriate bromomethylisocoumarin to give adduct III. Isocoumarin ring cleavage of III followed by desilylation, macrolactonization and demethoxymethylation-dehydration then gave I.

IT **140198-70-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 140198-70-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dimethoxy-14-methyl-, [1aS-(1aR*,2Z,4E,14R*,15aR*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:105970 CAPLUS
DOCUMENT NUMBER: 116:105970
TITLE: Preparation of acylradicicols as neoplasm inhibitors
INVENTOR(S): Sugimura, Yukio; Iino, Kimio; Tsujita, Yoshio; Shimada, Yoko; Kobayashi, Tomowo; Kagasaki, Takeshi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 94 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 460950	A1	19911211	EP 1991-305111	19910606
EP 460950	B1	19970305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 04226991	A2	19920817	JP 1991-134160	19910605
JP 3055967	B2	20000626		
CA 2044018	AA	19911207	CA 1991-2044018	19910606
WO 9118905	A1	19911212	WO 1991-GB909	19910606
W: SU				
CN 1059720	A	19920325	CN 1991-104853	19910606
CN 1035381	B	19970709		
HU 60743	A2	19921028	HU 1991-1893	19910606
AT 149498	E	19970315	AT 1991-305111	19910606
US 5597846	A	19970128	US 1994-311518	19940923
US 5650430	A	19970722	US 1995-473099	19950607

PRIORITY APPLN. INFO.: JP 1990-146299 A 19900606
US 1991-711217 B1 19910606
US 1992-988167 B1 19921209
US 1993-121956 B1 19930915
US 1994-246937 B1 19940520

OTHER SOURCE(S): MARPAT 116:105970
GI



AB Title compds. [I; R1, R2 = H, R3CO; R3 = H, (substituted) alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, aryl, aryloxy, heterocyclyl, cycloalkenyl, cycloalkyl], were prepared Thus, radicicol was acylated successively with stearoyl chloride and palmitoyl chloride in CH2Cl2 containing pyridine and dimethylaminopyridine to give 14-stearoyl-16-palmitoylradicicol. The latter at 200 mg/kg i.v. in mice gave 100% inhibition of growth of M5076 fibrosarcoma, vs. 5% for radicicol at 150 mg/kg.

IT **139249-27-7P 139270-30-7P 139270-31-8P**
139270-32-9P 139270-33-0P 139270-34-1P

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

139270-35-2P 139270-36-3P 139270-37-4P
139270-38-5P 139270-39-6P 139270-40-9P
139270-41-0P 139270-42-1P 139270-43-2P
139270-44-3P 139270-45-4P 139270-46-5P
139270-47-6P 139270-48-7P 139270-49-8P
139270-50-1P 139270-51-2P 139270-52-3P
139270-53-4P 139270-54-5P 139270-55-6P
139270-56-7P 139270-57-8P 139270-58-9P
139270-59-0P 139270-60-3P 139270-61-4P
139270-62-5P 139270-63-6P 139270-64-7P
139270-65-8P 139270-66-9P 139270-67-0P
139270-68-1P 139270-69-2P 139270-70-5P
139270-71-6P 139270-72-7P 139270-73-8P
139270-74-9P 139270-75-0P 139270-76-1P
139270-77-2P 139270-78-3P 139270-79-4P
139270-80-7P 139270-81-8P 139270-82-9P
139270-83-0P 139270-84-1P 139270-85-2P
139270-86-3P 139270-87-4P 139270-88-5P
139270-89-6P 139270-90-9P 139270-91-0P
139270-92-1P 139271-03-7P 139271-04-8P
139271-05-9P 139297-58-8P 139297-59-9P
139297-60-2P 139297-61-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as neoplasm inhibitor)

RN 139249-27-7 CAPLUS

CN Pentadecanoic acid, methyl-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



2 (D1—Me)

RN 139270-30-7 CAPLUS

CN Hexadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-34-1 CAPLUS

CN Docosanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-35-2 CAPLUS

CN Octadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-36-3 CAPLUS

CN Octadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-31-8 CAPLUS

CN Hexadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-32-9 CAPLUS

CN Octanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-33-0 CAPLUS

CN Docosanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 139270-37-4 CAPLUS

CN 9-Octadecenoic acid (92)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-38-5 CAPLUS

CN 9-Octadecenoic acid (92)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-39-6 CAPLUS

CN Hexanoic acid, 6-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-40-9 CAPLUS

CN Hexanoic acid, 6-[[(2,2,2-trichloroethoxy)carbonyl]amino]-, 8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-41-0 CAPLUS
CN Acetic acid, methoxy-, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-42-1 CAPLUS
CN Acetic acid, methoxy-, 8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)



RN 139270-43-2 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 9,11-bis(benzoyloxy)-8-chloro-1a,14,15,15a-tetrahydro-14-methyl- (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-44-3 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 9-(benzoyloxy)-8-chloro-1a,14,15,15a-tetrahydro-11-hydroxy-14-methyl- (9CI) (CA INDEX NAME)



RN 139270-45-4 CAPLUS
CN Acetic acid, phenoxy-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-46-5 CAPLUS
CN Benzeneacetic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-47-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-48-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-49-8 CAPLUS
CN Octadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-11-[(1-oxohexadecyl)oxy]-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-50-1 CAPLUS
CN 10-Undecenoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-51-2 CAPLUS
CN 10-Undecenoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-52-3 CAPLUS
CN Tetradecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-53-4 CAPLUS
CN Tetradecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-54-5 CAPLUS
CN Hexadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-9-[(1-oxotetradecyl)oxy]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)



RN 139270-55-6 CAPLUS
CN 9,12-Octadecadienoic acid (9Z,12Z)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-56-7 CAPLUS
CN 9,12-Octadecadienoic acid (9Z,12Z)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-57-8 CAPLUS
CN 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
1-yl)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-58-9 CAPLUS
CN Hexadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-9-[(1-oxo-10-undecenyl)oxy]-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-59-0 CAPLUS
CN Propanoic acid, 3-(methylthio)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-60-3 CAPLUS
CN Hexadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-9-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-11-yl ester (9CI) (CA INDEX NAME)



RN 139270-61-4 CAPLUS
CN 2-Octynoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-62-5 CAPLUS
CN Dodecanoic acid, 12-[[(2-propenyloxy)carbonyl]amino]-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-63-6 CAPLUS
CN Pentadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-64-7 CAPLUS
CN Heptadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-68-1 CAPLUS
CN 2-Propenoic acid, 3-phenyl-, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-69-2 CAPLUS
CN Benzenehexanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-70-5 CAPLUS
CN 2-Propenoic acid, 3-(2-furanyl)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-65-8 CAPLUS
CN Heptadecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-11-hydroxy-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139270-66-9 CAPLUS
CN 3,6,8-Trioxa-2-silatetracosan-24-oic acid, 2,2-dimethyl-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-67-0 CAPLUS
CN 2-Propenoic acid, 3-phenyl-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-71-6 CAPLUS
CN 2-Propenoic acid, 3-(2-thienyl)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-72-7 CAPLUS
CN Dodecanoic acid, 12-[[(triphenylmethyl)thio]amino]-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-73-8 CAPLUS
CN 9,12,15-Octadecatrienoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 139270-74-9 CAPLUS
CN Tridecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-75-0 CAPLUS
CN Dodecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-76-1 CAPLUS
CN Hexanoic acid, 6-(acetylthio)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-77-2 CAPLUS
CN Undecanoic acid, 11-cyano-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-78-3 CAPLUS
CN Dodecanoic acid, 12-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 139270-79-4 CAPLUS

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN Dodecanedioic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl dimethyl ester (9CI) (CA INDEX NAME)



RN 139270-80-7 CAPLUS
CN Hexanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-81-8 CAPLUS
CN Undecanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-82-9 CAPLUS
CN Eicosanoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-83-0 CAPLUS
CN Hexadecanoic acid, 16-hydroxy-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-84-1 CAPLUS
CN Dodecanoic acid, 12-hydroxy-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-85-2 CAPLUS
CN Decanoic acid, 10-hydroxy-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-86-3 CAPLUS
CN 9-Tetradecenoic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-87-4 CAPLUS
CN Dodecanoic acid, 12-amino-12-oxo-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-88-5 CAPLUS
CN Decanoic acid, 10-[(2-methoxyethoxy)methoxy]-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-89-6 CAPLUS
CN Decanoic acid, 10-(methoxymethoxy)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-90-9 CAPLUS
CN Dodecanoic acid, 12-[(2-methoxyethoxy)methoxy]-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139270-91-0 CAPLUS
CN Dodecanoic acid, 12-(methoxymethoxy)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139270-92-1 CAPLUS
CN Hexadecanoic acid, 16-(methoxymethoxy)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139271-03-7 CAPLUS
CN Hexadecanoic acid, 16-amino-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139271-04-8 CAPLUS
CN Hexadecanoic acid, 16-mercapto-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139271-05-9 CAPLUS
CN 9-Octadecenoic acid (9Z)-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-11-[(1-oxohexadecyl)oxy]-6H-oxireno[e][2]benzoxacyclotetradecin-9-yl ester (9CI) (CA INDEX NAME)



RN 139297-58-8 CAPLUS
CN Acetic acid, methoxy-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139297-59-9 CAPLUS
CN Benzeneacetic acid, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)

L59 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139297-60-2 CAPLUS
CN Acetic acid, chloro-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



RN 139297-61-3 CAPLUS
CN Hexadecanoic acid, 16-[(2-methoxyethoxy)methoxy]-, 8-chloro-1a,7,12,14,15,15a-hexahydro-14-methyl-6,12-dioxo-6H-oxireno[e][2]benzoxacyclotetradecin-9,11-diyl ester (9CI) (CA INDEX NAME)



L59 ANSWER 24 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1991:205393 CAPLUS
DOCUMENT NUMBER: 114:205393
TITLE: Microbial preparation of rhamnosyl derivatives of pharmaceutical phenolic compounds
INVENTOR(S): Nakagawa, Keiko; Nakajima, Mutsuo; Okazaki, Hisao; Takahashi, Hideji
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02211892	A2	19900823	JP 1989-258497	19891003

PRIORITY APPLN. INFO.: JP 1988-249487 19881003

AB Phenol group-containing pharmaceuticals having poor water solubility are rhamnosylated with Streptomyces lavendulae lavendulae. The rhamnose derivs. of these pharmaceuticals have improved water solubility S. lavendulae lavendulae SANK 64687 was shake-cultured for 6 days with thielavin A (I) 47→57 mg in 5% DMF at 28°; after centrifugation, the supernatant was processed to obtain rhamnosyl I 90 mg. In a test for inhibition of reverse transcriptase of human leukemia cirus, rhamnosyl I and I had ID50 of 29 and 32 μm, resp.

IT **133538-74-6P 133538-75-7P**
RL: PREP (Preparation)
(preparation of, by rhamnosylation with Streptomyces lavendulae lavendulae for improved water solubility)

RN 133538-74-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-11-[(6-deoxy-α-L-mannopyranosyl)oxy]-1a,14,15,15a-tetrahydro-9-hydroxy-14-methyl- (9CI) (CA INDEX NAME)



RN 133538-75-7 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9-[(6-deoxy-α-L-mannopyranosyl)oxy]-1a,14,15,15a-tetrahydro-11-hydroxy-14-methyl- (9CI) (CA INDEX NAME)

L59 ANSWER 24 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 25 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:61782 CAPLUS
DOCUMENT NUMBER: 114:61782
TITLE: Synthesis of monocillin IV dimethyl ether
AUTHOR(S): Kasar, R. A.; Wakharkar, R. D.; Chanda, B.; Ayyangar, N. R.
CORPORATE SOURCE: Natl. Chem. Lab., Pune, 411 008, India
SOURCE: Tetrahedron Letters (1990), 31(44), 6445-6
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The first total synthesis of monocillin IV di-Me ether (I) was achieved from Me 9-acetoxy-6-decenoate and orsellinic acid di-Me ether in two steps.
IT **131531-60-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of)
RN 131531-60-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,7,8,9,10-hexahydro-11-hydroxy-14,16-dimethoxy-3-methyl-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



L59 ANSWER 26 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:491441 CAPLUS
DOCUMENT NUMBER: 113:91441
TITLE: Azasterol-containing synergistic medical fungicidal compositions
INVENTOR(S): Onishi, Janet C.; Patchett, Arthur A.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 339709	A2	19891102	EP 1989-200933	19890413
EP 339709	A3	19900627		
EP 339709	B1	19930331		
R: CH, DE, FR, GB, IT, LI, NL				
US 4920109	A	19900424	US 1988-182615	19880418
CA 1321748	A1	19930831	CA 1989-596892	19890417
JP 02096530	A2	19900409	JP 1989-96529	19890418

PRIORITY APPLN. INFO.: US 1988-182615 19880418
OTHER SOURCE(S): MARPAT 113:91441
AB Synergistic medical fungicidal comps. comprise a 25-azasterol derivative (Markush given) and a known nonsteroidal fungicide nalidixic acid (50 μg/disk) combined with 25-azacholesterol (25 μg/mL) synergistically inhibited the growth of Candida albicans in vitro. Formulation examples are given.
IT **126840-61-7**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(fungicide, medical, synergistic)
RN 126840-61-7 CAPLUS
CN Chol-5-en-3-ol, 24-(dimethylamino)-, (3β)-, mixt. with [1aS-(1aR*,22,4E,14S*,15aR*)]-8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 12772-57-5
CMF C18 H17 Cl O6

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 26 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 1973-61-1
CMF C26 H45 N O

Absolute stereochemistry.



L59 ANSWER 27 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:193768 CAPLUS
DOCUMENT NUMBER: 112:193768
TITLE: Fungicidal compositions and method
INVENTOR(S): Onishi, Janet C.; Patchett, Arthur A.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 339708	A2	19891102	EP 1989-200932	19890413
EP 339708	A3	19900627		
R: CH, DE, FR, GB, IT, LI, NL				
US 4920113	A	19900424	US 1988-182616	19880418
US 4920111	A	19900424	US 1988-182605	19880418
US 4920112	A	19900424	US 1988-182536	19880418
US 4921844	A	19900501	US 1988-182601	19880418
JP 01311025	A2	19891215	JP 1989-96530	19890418

PRIORITY APPLN. INFO.: US 1988-182536 19880418
US 1988-182601 19880418
US 1988-182605 19880418
US 1988-182616 19880418
OTHER SOURCE(S): MARPAT 112:193768
AB Combination of azasterol compds. with certain fungistatic compds. (HMG-CoA synthase inhibitors) potentiated the activity of these compds. against fungi and mycotic infections. Thus, 25-azacholesterol (20 μg/mL) potentiated the antifungal activity of compds., such as nalidixic acid, lovastatin, terbinafine, etc. against Candida albicans. The compds. are formulated as tablets, capsules, etc.
IT **126840-61-7**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(fungicidal activity of, synergistic)
RN 126840-61-7 CAPLUS
CN Chol-5-en-3-ol, 24-(dimethylamino)-, (3β)-, mixt. with [1aS-(1aR*,22,4E,14S*,15aR*)]-8-chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 12772-57-5
CMF C18 H17 Cl O6

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 27 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 1973-61-1
CMF C26 H45 N O

Absolute stereochemistry.



L59 ANSWER 28 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1987:493204 CAPLUS
DOCUMENT NUMBER: 107:93204
TITLE: Minor metabolites of Monocillium nordinii
AUTHOR(S): Ayer, William A.; Pena-Rodriguez, Luis
CORPORATE SOURCE: Dep. Chem., Univ. Alberta, Edmonton, AB, T6G 2G2, Can.
SOURCE: Phytochemistry (1987), 26(5), 1353-5
CODEN: PYTCAS; ISSN: 0031-9422
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I, R=H
II, R=OH

AB Examination of the metabolites produced in liquid still culture by M. nordinii
resulted in the isolation and characterization of two new compds., nordinone (I) and nordinonediol (II), as well as the known compds. monorden, monocillins I-IV and sterigmatocystin. The transformation of monocillin I into monorden is reported.

IT **75207-11-3**, Monocillin III **75207-12-4**, Monocillin V
75207-13-5, Monocillin I **75207-14-6**, Monocillin IV
75207-15-7, Monocillin II
RL: BIOL (Biological study)
(from Monocillium nordinii)

RN 75207-11-3 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl- (9CI) (CA INDEX NAME)



RN 75207-12-4 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, (1aS,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L59 ANSWER 28 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Currently available stereo shown.



RN 75207-13-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 75207-14-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,7,8,9,10-hexahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 75207-15-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,7,8-tetrahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



IT **109872-63-1 109872-64-2**

L59 ANSWER 28 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RL: BIOL (Biological study)
(from Monocillium nordinii, mol. structure of)

RN 109872-63-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,5,6,7,8,9,10-octahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 109872-64-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,5,6,7,8,9,10-octahydro-5,6,14,16-tetrahydroxy-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 29 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1981:121499 CAPLUS
DOCUMENT NUMBER: 94:121499
TITLE: Dialkoxy monorden derivatives
INVENTOR(S): Calton, Gary J.
PATENT ASSIGNEE(S): W. R. Grace and Co., USA
SOURCE: U.S., 3 pp. Cont.-in-part of U.S. Ser. No. 874,348, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4228079	A	19801014	US 1978-955705	19781030
JP 54112885	A2	19790904	JP 1979-8302	19790129
SE 7900855	A	19790802	SE 1979-855	19790131
DK 7900402	A	19790802	DK 1979-402	19790131
NO 7900320	A	19790802	NO 1979-320	19790131
GB 2013672	A	19790815	GB 1979-3327	19790131
GB 2013672	B2	19820609		
DE 2903997	A1	19790906	DE 1979-2903997	19790131
FR 2416231	A1	19790831	FR 1979-2671	19790201
FR 2416231	B1	19810814		

PRIORITY APPLN. INFO.: US 1978-874348 19780201
US 1978-874207 19780201
US 1978-955705 19781030

GI



I

AB The monorden derivs. I (R = Pr, Me2CH) were prepared Thus, I (R = H) was treated with H2CO3 and PrI to give I (R = Pr). The ED50 of I (R = Pr) against tumorous human nasopharynx cells was 3.1 μg/mL. The nematocidal LC50 of I (R = Me2CH) was 0.8 mg/mL.

IT **71762-13-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antitumor activity of)

RN 71762-13-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-14-methyl-9,11-dipropoxy- (9CI) (CA INDEX NAME)

L59 ANSWER 29 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **71762-12-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 71762-12-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-diethoxy-1a,14,15,15a-tetrahydro-14-methyl- (9CI) (CA INDEX NAME)



IT **71762-14-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, antitumor and nematocidal activity of)

RN 71762-14-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-14-methyl-9,11-bis(1-methylethoxy)- (9CI) (CA INDEX NAME)



L59 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1980:582711 CAPLUS
DOCUMENT NUMBER: 93:182711
TITLE: The isolation, identification, and bioassay of the antifungal metabolites produced by Monocillium nordinii
AUTHOR(S): Ayer, William A.; Lee, Sing Ping; Tsuneda, Akihiko; Hiratsuka, Yasuyuki
CORPORATE SOURCE: Dep. Chem., Univ. Alberta, Edmonton, AB, T6G 2G2, Can.
SOURCE: Canadian Journal of Microbiology (1980), 26(7), 766-73
CODEN: CJMIAZ; ISSN: 0008-4166
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The metabolites produced when M. nordinii (Bourchier) W. Gams, a destructive mycoparasite of pine stem rusts, is grown in liquid culture were separated and identified. The metabolites include the known compound monorden (I) and 5 new substances, monocillin I, monocillin II, monocillin III, monocillin IV, and monocillin V. Structural assignments and chemical correlations of the 5 new compds. are reported and the absolute configuration of monorden is assigned. The antifungal spectra of the 3 major metabolites are reported. I and monocillin I show pronounced activity against a wide variety of fungi, including Ceratocystis ulmi, the cause of Dutch elm disease. Extraction of the mycelium yielded averufin, along with a pigment C18H12O6, as yet unidentified.

IT **75207-11-3 75207-12-4 75207-13-5 75207-14-6 75207-15-7**
RL: FORM (Formation, nonpreparative)
(formation of, by Monocillium nordinii, fungicidal activity in relation to)

RN 75207-11-3 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 75207-12-4 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, (1aS,15aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Currently available stereo shown.



RN 75207-13-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 75207-14-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,7,8,9,10-hexahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 75207-15-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 3,4,7,8-tetrahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)

L59 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **75207-16-8P 75207-17-9P 75207-18-0P**
75207-19-1P 75207-20-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 75207-16-8 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dimethoxy-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 75207-17-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4-dihydro-14,16-dimethoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 75207-18-0 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 1a,4,5,14,15,15a-hexahydro-9,11-dimethoxy-14-methyl- (9CI) (CA INDEX NAME)

L59 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 75207-19-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 13-chloro-3,4,5,6,7,8,9,10-octahydro-5-hydroxy-14,16-dimethoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 75207-20-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,11(12H)-dione, 5-(benzoyloxy)-13-chloro-3,4,5,6,7,8,9,10-octahydro-14,16-dimethoxy-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1979:575316 CAPLUS
DOCUMENT NUMBER:	91:175316
TITLE:	Dialkoxymonordens
PATENT ASSIGNEE(S):	W. R. Grace and Co., USA
SOURCE:	Belg., 11 pp.
	CODEN: BEXXAL
DOCUMENT TYPE:	Patent
LANGUAGE:	French
FAMILY ACC. NUM. COUNT:	3
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 873856	A1	19790516	BE 1979-193203	19790131
PRIORITY APPLN. INFO.:			US 1978-874348	19780201

GI



I

AB The title compds. I (R = C2-8 alkyl) were prepared by the reaction of monorden with RI and K2CO3. Thus, 0.0055 mol monorden, 0.0055 mol K2CO3, and 0.0082 mol EtI was refluxed in 8.3 mL acetone 5-6 h to give diethoxymonorden (II). Similarly prepared were dipropoxymonorden (III) and diisopropoxymonorden (IV). The ED50 for II-IV were 1.9 μg, 3.1 μg and 3.9 μg, resp., against tumor cells. The LD50 for II against nematodes was 0.2 mg/mL.

IT **71762-13-5P 71762-14-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and anticancer activity of)
RN 71762-13-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-14-methyl-9,11-dipropoxy- (9CI) (CA INDEX NAME)



RN 71762-14-6 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-14-methyl-9,11-bis(1-methylethoxy)- (9CI) (CA INDEX NAME)

L59 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **71762-12-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation anticancer activity, and nematocidal activity of)
RN 71762-12-4 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-9,11-diethoxy-1a,14,15,15a-tetrahydro-14-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 32 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1979:456564 CAPLUS
DOCUMENT NUMBER: 91:56564
TITLE: A new synthetic method for aromatic type medium and large membered lactones based on intramolecular alkylation of ω-haloalkyl 2-phenylthiomethylbenzoate, and its application to the synthesis of (±)lasiodiplodin using a butadiene telomer
AUTHOR(S): Takahashi, Takashi; Kasuga, Kazuyuki; Tsuji, Jiro
CORPORATE SOURCE: Tokyo Inst. Technol., Tokyo, Japan
SOURCE: Tetrahedron Letters (1978), (49), 4917-20
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 91:56564
GI



II



III



VI

AB Esterification of 2-(PhSCH2)C6H4COCl (I) with MeCH(OH)(CH2)mI (m = 8, 9) in CH2Cl2 gave 85-95% 2-PhSCH2C6H4CO2CHMe(CH2)mI, which underwent intramol. alkylation on treatment with (Me3Si)2NH in THF to give 71-5% lactones II (R = R1 = H, n = 4, 5). Oxidation of II (R = R1 = H, n = 4) with NaIO4 followed by PhMe reflux gave III quant. I was esterified by MeCH(OH)(CH2)3CH:CHCH2Cl (IV), prepared in five steps from butadiene, to give 2-(PhSCH2)C6H4CO2CHMe(CH2)3CH:CHCH2Cl, which was cyclized to 41% II (R = H, R1R1 = bond, n = 2). Similarly, the ester from IV and 2,4,6-(MeO)2(PhSCH2)C6H2COCl, prepared in six steps from 6,2,4-Me(HO)2C6H2CO2Me, was cyclized to give 40% II (R = MeO, R1R1 = bond, n = 2) (V). V was heated with Raney Ni in EtOH to give 70% lasiodiplodin derivative VI.
IT **70719-41-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and S-oxidation of)

L59 ANSWER 32 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 70719-41-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-3-methyl-12-(phenylthio)- (9CI) (CA INDEX NAME)



L59 ANSWER 33 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1970:563432 CAPLUS
DOCUMENT NUMBER: 89:163432
TITLE: Synthesis of dideoxyzearalane and related compounds
INVENTOR(S): Robertson, Donald Edwin
PATENT ASSIGNEE(S): IMC Chemical Group, Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4088658	A	19780509	US 1976-738929	19761104

PRIORITY APPLN. INFO.: US 1976-738929 19761104
GI



I



II

AB The dideoxyzearalanes I (X = CH2, CO) were prepared by sulfonation of II (Y = CH2, CO, CHOH; Z = single or double bond) followed by hydrogenolysis. Thus, zearalane was treated with MeSO2Cl to give 02.04-bis(methylsulfonyl)zearalane, which was hydrogenated to give dideoxyzearalane. Orally administered dideoxyzearalane increased weight gain in cattle.
IT **67972-08-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenolysis of)
RN 67972-08-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-3-methyl-14,16-bis[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



L59 ANSWER 34 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1977:582597 CAPLUS
DOCUMENT NUMBER: 87:182597
TITLE: Treating cholesterolemia by administering resorcylic acid lactone derivatives
INVENTOR(S): Hidy, Phil H.; Baldwin, Robert S.
PATENT ASSIGNEE(S): IMC Chemical Group, Inc., USA
SOURCE: U.S., 16 pp. Division of U.S. 3,965,275.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4035504	A	19770712	US 1976-663149	19760302
US 3965275	A	19760622	US 1975-576639	19750512

PRIORITY APPLN. INFO.: US 1965-512199 19651207
US 1970-28913 19700415
US 1972-289456 19720915
US 1974-441150 19740211
US 1975-576639 19750512
GI



I

AB Compns. for estrogenic therapy of human cholesterolemia without feminizing and other undersirable side effects contain a 0.2-2000 mg daily dose of a resorcylic acid lactone derivative I (R = H, lower alkyl, or lower saturated acyl; Z = CH2, CHOH, or C:O; X = CH2CH2, CH:CH). For example, a fermentation estrogenic substance (FES)(I: R = H, Z = C:O, X = CH:CH) [17924-92-4] was isolated from the fermentation medium of Gibberella zeae cultivated in corn infusion. FES was hydrogenated in the presence of Raney Ni to give tetrahydro-FES [55331-29-8]. Tetrahydro-FES (246 g) was triturated with 60 g lactose and then mixed with 20 g silicic acid, hydrolyzed starch and H2O. The paste was dried and tabletted with 2 g Mg stearate to give tablets each containing 150 mg tetrahydro-FES. A 51-year-old woman with hot flashes, irritability, and an early prolific endometrium with scarce mitotic activity showed complete disappearance of hot flashes, improved psychol. state and 3 day withdrawal bleeding when treated with tetrahydro-FES at 400 mg/day for 20 days.
IT **64498-17-5P**
RL: PREP (Preparation)
(preparation of, as estrogenic hormone)
RN 64498-17-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 16-(acetyloxy)-3,4,5,6,7,8,9,10,11,12-decahydro-14-methoxy-3-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L59 ANSWER 34 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 35 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1976:554438 CAPLUS
DOCUMENT NUMBER: 85:154438
TITLE: Pharmaceutical composition for estrogenic therapy
INVENTOR(S): Hidy, Phil H.; Baldwin, Robert S.
PATENT ASSIGNEE(S): Commercial Solvents Corp., USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3965275	A	19760622	US 1975-576639	19750512
US 4035504	A	19770712	US 1976-663149	19760302
PRIORITY APPLN. INFO.:			US 1965-512199	19651207
			US 1970-28913	19700415
			US 1972-289456	19720915
			US 1974-441150	19740211
			US 1975-576639	19750512

GI



AB In monkeys treated with zearalanol (I) [26538-44-3] (0.9 mg/kg), 4 of 6 animals had withdrawal bleeding following cessation of treatment indicating uterine stimulation; spotting was observed in 5 of 6 animals. This response suggest that the 0.9 mg/kg dose was stimulating endometrial development but was inadequate to maintain it. Vaginal changes were comparable with those observed in animals treated with I at 1.8 mg/kg. Sex skin changes were present and the degree of coloration was essentially the same as was observed in the high dose group. In women, I (0.2-2000 mg/day) was effective in postmenopausal estrogenic therapy.

IT **7396-62-5 60569-17-7 60569-18-8**
RL: BIOL (Biological study)
(estrogen therapy with, after menopause)

RN 7396-62-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,11,10,12-decahydro-14,16-dimethoxy-3-methyl- (9CI) (CA INDEX NAME)

L59 ANSWER 35 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 60569-17-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-16-hydroxy-14-methoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 60569-18-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14-hydroxy-16-methoxy-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 36 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1976:524314 CAPLUS
DOCUMENT NUMBER: 85:124314
TITLE: Zearaline glycoside compounds
INVENTOR(S): Robertson, Donald E.
PATENT ASSIGNEE(S): Commercial Solvents Corp., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3960835	A	19760601	US 1974-434405	19740118
PRIORITY APPLN. INFO.:			US 1974-434405	19740118

GI



AB Five I (R = H, Ac; X = (CH2)2, CH:CH; Z = CH2, CO, CHOH), useful as ruminant growth promoters, were prepared by treatment of zearalenone, zeralanol, zearalane, or zearalanone with α-acetobromoglucose (II). Thus, trans-zearalenone reacted with II in aqueous NaOH for .apprx.3 hr at room temperature to give I (R = Ac; X = CH:CH; Z = CO), which, at a dose of 25 μug/g feed in mice, increased the uterine weight to 0.135% of body weight as compared with 0.055% for control mice.

IT **60505-14-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anabolic and estrogenic activity of)

RN 60505-14-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-16-hydroxy-3-methyl-14-[(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L59 ANSWER 36 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 37 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1976:58947 CAPLUS
DOCUMENT NUMBER: 84:58947
TITLE: Synthesis of zearalanes and related compounds and intermediates useful in the syntheses
INVENTOR(S): Urry, Wilbert H.; Mullenbach, Guy T.
PATENT ASSIGNEE(S): Commercial Solvents Corp., USA
SOURCE: U.S., 23 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3901921	A	19750826	US 1972-247342	19720425

PRIORITY APPLN. INFO.: US 1972-247342 19720425
GI For diagram(s), see printed CA Issue.
AB (R,S)-norzearalane (I) was prepared in 9 steps from H2C:CH(CH2)8CHO and (HO2C)2CH2. (R,S)-zearalane (II) and the dimeric dilactone (III) from 6-(10-hydroxyundecyl)-β-resorcylic acid were prepared from 10-undecen-1-ol in 12 steps, and the dimeric dilactone (IV) of 2,4-bis(benzyloxy)-6-(4-hydroxypentyl)benzoic acid was prepared in 9 steps from 3-hydroxy-1,5-hexadiene. I-IV are useful anabolic agents (no data) in the production of animals such as sheep and cattle.
IT **58007-99-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)
RN 58007-99-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-3-methyl-14,16-bis(phenylmethoxy)- (9CI) (CA INDEX NAME)



IT **23791-62-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23791-62-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)

L59 ANSWER 37 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 38 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:526456 CAPLUS
DOCUMENT NUMBER: 77:126456
TITLE: (Hydroxyamino)zearalane
INVENTOR(S): Hodge, Edward B.; Hidy, Phil H.; Wehrmeister, Herbert L.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: Ger., 3 pp.
CODEN: GWXXAW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1543473		19720531		

PRIORITY APPLN. INFO.: US 1965-432813 19650215
GI For diagram(s), see printed CA Issue.
AB The title compound (I) was obtained by oximating zearalenone and reducing with a PdO-C catalyst. In lambs I gave an average weight gain of 0.6 lb/day at a
feed conversion ratio of 600 kg/100 kg gain vs. 0.5 lb/day at 774 kg/100 kg gain in controls. I has <1% the estrogenic activity of diethylstilbestrol.
IT **5553-45-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use as animal growth substances)
RN 5553-45-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-7-(hydroxyamino)-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 39 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:433126 CAPLUS
DOCUMENT NUMBER: 77:33126
TITLE: Animal feed containing an antibacterial and growth-promoting additive
INVENTOR(S): Urry, Wilbert H.; Wehrmeister, Herbert L.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: Fr., 13 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2069593	A5	19710903	FR 1970-41321	19701118
US 3764614	A	19731009	US 1970-11879	19700216
ZA 7006764	A	19710728	ZA 1970-6764	19701005
CH 549011	A	19740515	CH 1970-14775	19701006
IL 35406	A1	19731128	IL 1970-35406	19701007
GB 1272874	A	19720503	GB 1970-1272874	19701020
ES 387529	A1	19740716	ES 1971-387529	19710108
SE 374364	B	19750303	SE 1971-718	19710121
DK 127813	B	19740114	DK 1971-651	19710212

PRIORITY APPLN. INFO.: US 1970-11879 19700216
GI For diagram(s), see printed CA Issue.
AB The reaction of a deoxytetrahydro fermentation estrogen and sulfuryl chloride (1:1 or 1:2) at 0-25° yields the monochloro derivative (I) or the 3,5-dichloro derivative (II), which may be used as an antibacterial and growth promotive feed additive. Similarly prepared are 7 other monochloro compds. Another starting material is 4-benzyl ether dihydro fermentation estrogen. The additive in the feed for youg cattle, pigs, sheep, and pullets is given to supply the following mg per day of the compds.: 5-90, 5-50, 1-15, resp., for the 1st 3, and 12-36 mg total for the pullets.
IT **34462-53-8 34462-54-9 37630-27-6 37630-28-7 37630-29-8**
RL: BIOL (Biological study)
(as feed additive)
RN 34462-53-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 13-chloro-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 34462-54-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 13,15-dichloro-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)

L59 ANSWER 39 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 37630-27-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 13-chloro-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dimethoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 37630-28-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 13-chloro-14,16-diethoxy-3,4,5,6,7,8,9,10,11,12-decahydro-3-methyl- (9CI) (CA INDEX NAME)



RN 37630-29-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 16-(acetyloxy)-13-chloro-3,4,5,6,7,8,9,10,11,12-decahydro-14-methoxy-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 40 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:419323 CAPLUS
DOCUMENT NUMBER: 77:19323
TITLE: Chemical modifications of zearalenone. I
AUTHOR(S): Jensen, N. P.; Brown, R. D.; Schmitt, S. M.; Windholz, T. B.; Patchett, A. A.
CORPORATE SOURCE: Dep. Synth. Chem. Res., Merck Sharp and Dohme Res. Lab., Rahway, NJ, USA
SOURCE: Journal of Organic Chemistry (1972), 37(10), 1639-47
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Chemical transformations of the aliphatic portion of the mold metabolite zearalenone were examined. Reactions at the C'-6 ketone and the C'-1 double bond and positions adjacent to these reaction centers are reported. The reactions are regioselective.
IT **29181-06-4P 29181-19-9P 34290-11-4P 34290-12-5P 34290-13-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 29181-06-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo-, [3S-(3R*,6S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 29181-19-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo-, [3S-(3R*,6R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 34290-11-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 14,16-bis(acetyloxy)-6-[(acetyloxy)methylene]-3,4,5,6,7,8,9,10,11,12-decahydro-3-methyl-, (S-(Z))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L59 ANSWER 40 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 34290-12-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 14,16-bis(acetyloxy)-6-[(acetyloxy)methylene]-3,4,5,6,7,8,9,10,11,12-decahydro-3-methyl-, [S-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 34290-13-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,6(5H)-dione, 3,4,7,8,9,10,11,12-octahydro-14,16-dimethoxy-3-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L59 ANSWER 41 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 41 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:3717 CAPLUS
DOCUMENT NUMBER: 76:3717
TITLE: 3-Chloro- and 3,5-dichloro-4,6-dihydroxy-2-(10-hydroxyundecyl)benzoic acid μ-lactone
INVENTOR(S): Urry, Wilbert H.; Wehrmeister, Herbert L.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: Ger. Offen., 18 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2052097	A	19710826	DE 1970-2052097	19701023
US 3764614	A	19731009	US 1970-11879	19700216
ZA 7006764	A	19710728	ZA 1970-6764	19701005
CH 549011	A	19740515	CH 1970-14775	19701006
IL 35406	A1	19731128	IL 1970-35406	19701007
GB 1272874	A	19720503	GB 1970-1272874	19701020
ES 387529	A1	19740716	ES 1971-387529	19710108
SE 374364	B	19750303	SE 1971-718	19710121
DK 127813	B	19740114	DK 1971-651	19710212

PRIORITY APPLN. INFO.: US 1970-11879 19700216
GI For diagram(s), see printed CA Issue.
AB Title compds. (I) useful as growth stimulants in feed for meat producing animals, were prepared by chlorination of 4,6-dihydroxy-2-(10-hydroxyundecyl)benzoic μ-lactone (II). Thus, II was treated with equimolar SO2Cl2 in CHCl3 3 hr at 24° to give I (R = H) (III). Reaction of 1 mole II with 2.2 moles SO2Cl2 gave I (R = Cl). I were given to young cattle, hogs, and sheep in 1-50 mg/day doses. III was given to chicken in 12-16 mg doses within the first 9 weeks.
IT **34462-53-8P 34462-54-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, and use as feed additive)
RN 34462-53-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 13-chloro-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 34462-54-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 13,15-dichloro-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)

L59 ANSWER 42 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:3716 CAPLUS
DOCUMENT NUMBER: 76:3716
TITLE: 3,5-Dibromo-4,6-dihydroxy-2-(10-hydroxyundecyl)benzoic acid μ-lactone
INVENTOR(S): Wehrmeister, Herbert L.; Hodge, Edward B.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2052096	A	19710826	DE 1970-2052096	19701023
US 3751431	A	19730807	US 1970-11880	19700216
CH 542839	A	19731130	CH 1970-14766	19701006
IL 35407	A1	19731128	IL 1970-35407	19701007
GB 1273288	A	19720503	GB 1970-1273288	19701021
FR 2069594	A5	19710903	FR 1970-41322	19701118
ES 387676	A1	19730501	ES 1971-387676	19710111
DK 127812	B	19740114	DK 1971-650	19710212
SE 374365	B	19750303	SE 1971-1881	19710215

PRIORITY APPLN. INFO.: US 1970-11880 19700216
GI For diagram(s), see printed CA Issue.
AB Title compound (I), useful as growth stimulant in feed for meat producing animals, was prepared by bromination of 4,6-dihydroxy-2-(10-hydroxyundecyl)benzoic μ-lactone (II). Thus, 5 g II reacted with Br in CHCl3 at room temperature to give 2.46 g I. I was given to young cattle in 5-20
mg/day doses, to hogs in 5-50 mg/day doses, and to chickens in 12-36 mg doses within the first 9 weeks.
IT **34462-52-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use as feed additive)
RN 34462-52-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 13,15-dibromo-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 43 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1971:400834 CAPLUS
DOCUMENT NUMBER: 75:834
TITLE: Uterotrophic and antiimplantation activities of certain resorcylic acid lactone derivatives
AUTHOR(S): Brooks, J. R.; Steelman, Sanford L.; Patanelli, D. J.
CORPORATE SOURCE: Dep. Endocrinol., Merck Inst. Ther. Res., Rahway, NJ, USA
SOURCE: Proceedings of the Society for Experimental Biology and Medicine (1971), 137(1), 101-4
CODEN: PSEBAA; ISSN: 0037-9727
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB A determination of the uterotropic and antifertility properties of the resorcylic acid lactone derivative, zearalane (I), showed that I had less than 1/10th the activity of its derivs. bearing 7'-formyl or 7'-carboxyl groups. In comparison with diethylstilbestrol, I was .apprx.1 + 10-4 times as active. No unequivocal separation of estrogenic and antiimplantation activities was observed in any of the compds. tested.
IT **31571-37-6 31571-38-7**
RL: BIOL (Biological study)
(isomers, estrogenicity and implantation-inhibiting activities of)
RN 31571-37-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo- (8CI, 9CI) (CA INDEX NAME)



RN 31571-38-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxylic acid, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo- (8CI, 9CI) (CA INDEX NAME)



L59 ANSWER 44 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1970:520524 CAPLUS
DOCUMENT NUMBER: 73:120524
TITLE: Physiologically active zearalane derivatives
INVENTOR(S): Jensen, Norman P.; Windholz, Thomas B.
PATENT ASSIGNEE(S): Merck and Co., Inc.
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2009106	A	19700917	DE 1970-2009106	19700226
US 3621036	A	19711116	US 1969-803048	19690227
NL 7001868	A	19700831	NL 1970-1868	19700210
GB 1290263	A	19720927	GB 1970-1290263	19700223
FR 2034573	A5	19701211	FR 1970-7181	19700227
FR 2034573	B1	19730810		
CH 540906	A	19731015	CH 1970-2931	19700227

PRIORITY APPLN. INFO.: US 1969-803048 19690227
GI For diagram(s), see printed CA Issue.
AB The title compds. (I) are prepared Zearalenone 2',4'-dibenzyl ether was condensed successively with HCO2Et and cyclohexanol in the presence of NaH and p-MeC6H4SO2Cl, resp., and reduced successively with NaBH4 and H (Pd/C) to give an isomeric mixture of I (R = CHO, R1 = OH, R2 = R3 = H) (II) which was subjected to Jones oxidation [to give I (R = CO2H)], reduced [to give I (R = CH2OH)], treated successively with p-MeC6H4SO2Cl-pyridine and KCN, hydrolyzed and esterified [to give I (R = CH2CO2Me)], and hydrolyzed to give I (R = CH2CO2H, R1 = OH, R2 = R3 = H). Nitration of I (R = CO2H, R1 = OH, R2 = R3 = H) gave the corresponding I (R3 = NO2): 3 addnl. 5'-NO2 compds. were also prepared II was etherated with successive tetrahydropyran and 1-phenyl-5-chlorotetrazole, hydrogenated (Pt/C) and hydrolyzed to give I (R = CH2OH, R1-R3 = H); 2 addnl. 2'-deoxy compds. were also prepared Methylation of II with Me2SO4 gave I (R = CHO, R1 = OMe, R2 = Me, R3 = H) as well as I (R = CHO, R1 = OMe, R2 = R3 = H) which was acetylated to give I (R = CHO, R1 = OMe, R2 = Ac, R3 = H). Numerous esters and monoester-monoethers of II were also prepared
IT **29181-06-4P 29181-07-5P 29181-08-6P**
29181-09-7P 29181-10-0P 29181-11-1P
29181-12-2P 29181-13-3P 29181-19-9P
29348-36-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 29181-06-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo-, [3S-(3R*,6S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L59 ANSWER 44 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 29181-07-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dimethoxy-3-methyl-1-oxo-, stereoisomer (8CI) (CA INDEX NAME)



RN 29181-08-6 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14-hydroxy-16-methoxy-3-methyl-1-oxo-, stereoisomer (8CI) (CA INDEX NAME)



RN 29181-09-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo-, diacetate, stereoisomer (8CI) (CA INDEX NAME)



RN 29181-10-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14-hydroxy-16-methoxy-3-methyl-1-oxo-, acetate, stereoisomer (8CI) (CA INDEX NAME)

L59 ANSWER 44 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 29181-11-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo-, 14-acetate, stereoisomer (8CI) (CA INDEX NAME)



RN 29181-12-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 14-ethoxy-3,4,5,6,7,8,9,10,11,12-decahydro-16-methoxy-3-methyl-1-oxo-, stereoisomer (8CI) (CA INDEX NAME)



RN 29181-13-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo-, 16-acetate propionate, stereoisomer (8CI) (CA INDEX NAME)



RN 29181-19-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-1-oxo-, [3S-(3R*,6R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L59 ANSWER 44 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 29348-36-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-6-carboxaldehyde, 14-(benzyloxy)-3,4,5,6,7,8,9,10,11,12-decahydro-16-hydroxy-3-methyl-1-oxo-, stereoisomer (8CI) (CA INDEX NAME)



L59 ANSWER 45 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1970:414502 CAPLUS
DOCUMENT NUMBER: 73:14502
TITLE: Synthesis of estrogenic compounds
INVENTOR(S): Wehrmeister, Herbert L.; Robertson, Donald E.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1924363	A	19691211	DE 1969-1924363	19690513
IL 31962	A1	19740114	IL 1969-31962	19690406
GB 1224942	A	19710310	GB 1969-1224942	19690512
FR 2008561	A5	19700123	FR 1969-15382	19690513
BE 733089	A	19691016	BE 1969-733089	19690514
NL 6907470	A	19691118	NL 1969-7470	19690514
CH 517091	A	19711231	CH 1969-517091	19690514
US 3812155	A	19740521	US 1970-78925	19701007

PRIORITY APPLN. INFO.: US 1968-729409 19680515
GI For diagram(s), see printed CA Issue.
AB 2-(10-Hydroxyundecyl)benzoic acid lactone (I), an estrogenic agent stimulating the growth of meat-producing animals, is prepared 10-Undecylenic acid (530 g) is refluxed 2.5 hr with 1.433 kg Ac2O to give 96% 10-undecylenic anhydride, b0.05 225°, which (465 g) with 178 g phthalic anhydride and 36 g NaOAc gives 51% 3-(9-decenylidene)phthalide (II), b0.3 171-83°. II (54 g) is refluxed 3 hr with 200 g NaOH in 50% aqueous tetrahydrofuran and 37.8 g NaBH4 added to give 69% 3-(9-decenyl)phthalide (III), b0.1 146-9°. To 12.8 g Hg(OAc)2 in 100 ml H2O and 30 ml tetrahydrofuran is added 10.9 g III 6 g NaOH added, 140 ml EtOH added, and 3.78 g NaBH4 in 3N NaOH added to give 80% 3-(9-hydroxydecyl)phthalide (IV) and 10% III. A solution of 2 g IV in 15 ml tetrahydrofuran and 15 ml 20% aqueous NaOH is refluxed 2 hr, the solvent distilled, the solution adjusted to pH 10.2, 5% Pd/C added, and the mixture hydrogenated to 86% 2-(10-hydroxyundecyl)benzoic acid (V). V (0.9 g) 0.72 g Et3N, and 3.5 ml 12.5% COCl2 in C6H6 gave 25% I. 6-(10-Hydroxyundecenyl)-β-resorcylic acid lactone (30.6 g), 34.8 g 2-chlorobenzoxazole, and 35.4 g K2CO3 in 400 ml AcMe are refluxed 24 hr to give O,O-di(2-benzoxazolyl)-6-(10-hydroxyundecenyl)-β-resorcylic acid lactone (VI). VI (46.1 g) in EtOH is reduced with H and 5 g 5% Pd/C and the 43.5 g oil obtained heated with n-C6H14 to precipitate 21 g benoxazolidone, m. 136-8°, and yield 89% (+)-I oil. Saponification of 16.2 g (+)-I in Me2SO with 20% aqueous NaOH gives 90% (+)-V yellow oil. (+)-V is converted to (+)-I by treating with Et3N and COCl2 in C6H6.
IT **17397-59-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as estrogenic agent)

L59 ANSWER 45 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 17397-59-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-3-methyl-, (+)- (8CI) (CA INDEX NAME)

Rotation (+).



L59 ANSWER 46 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1969:87324 CAPLUS
DOCUMENT NUMBER: 70:87324
TITLE: Zearalane and intermediates
INVENTOR(S): Urry, Wilbert H.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: S. African, 20 pp.
CODEN: SFXXAB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 6706819		19680618		
FR 1557071			FR	
GB 1157199			GB	
US 3631199		19710000	US	

PRIORITY APPLN. INFO.: US 19661213
AB Zearalane (cf. U.S. 3,239,341) (I) was prepared as follows. A solution of MeMgI in ether (prepared from 7.76 g. Mg, 45 g. MeI, and 45 ml. ether) was treated dropwise with 42 g. 10-undecenal in 50 ml. ether and the mixture refluxed 16 hrs. to give 96% 11-hydroxy-1-dodecane (Ia), b0.3 77-8°. Ia (25 g.) in 700 ml. CH2Cl2 containing 2 ml. H2SO4 was reacted with Me2C:CH2 by bubbling the gas through the solution for 48 hrs. at room temperature to give 67% 11-tert-butoxy-1-dodecene (II), b0.3 71-3°. II (22 g.) was reacted with diisoamylborane (prepared by reacting 3.2 g. NaBH4, 15.5 g. BF3, and 15.4 g. 2-methyl-2-butene in 80 ml. diglyme at 0° for 24 hrs.) by vigorous stirring at 25° for 2.5 hrs. after which 30 ml. 3N NaOH and 30 ml. 30% H2O2 were added to give 73% 11-tert-butoxy-1-dodecanol (III), b0.2 120-1°. III (17.2 g.) in 30 g. pyridine was treated with 16.7 g. p-MeC6H4SO2Cl at 20° for 5 hrs. to give 92% crude tosylate (IV). IV (25 g.) was added to a solution of 60 g. NaHCO3 in 60 g. Me2SO at 150° with stirring for 4 min. to give 70% crude 11-tert-butoxydodecanal (V). V (11 g.) in 25 g. pyridine was reacted with 8 g. malonic acid at 70° for 24 hrs., 4 g. malonic acid added, and the solution heated for 36 hrs. to give 31% crude 13-tert-butoxy-trans-2-tetradecenoic acid (VI). VI (26 g.) in ether at 0° was reacted with a solution of CH2N2 in ether to give 14 g. Me 13-tert-butoxy-trans-2-tetradecenoate (VII), b0.4 112°. VII (14 g.), 5.05 g. Et acetoacetate, and NaOEt in EtOH (prepared from 1.1 g. Na and 25 ml. EtOH) was refluxed for 24 hrs. to give 13 g. monosodium Et 6-(10-tert-butoxyundecyl)dihydro-β-resorcylate (VIII). VIII (13 g.) in 100 ml. H2O was vigorously stirred while adding 4.8 g. Br dropwise to give 12 g. crude Et 3-bromo-6-(10-tert-butoxyundecyl)-dihydroresorcylate (IX) (does not solidify completely after 12 hrs. at 0°). IX was refluxed with NaOEt solution (prepared from 6 g. Na and 150 ml. anhydrous EtOH) for 3 hrs. to give Et 6-(10-tert-butoxyundecyl)resorcylate (X). X (9 g.) in 100 ml. F3CCO2H at 0° for 1 hr. gave 6 g. crude Et 6-(10-hydroxyundecyl)resorcylate (XI) or 13 g. of the Na salt is treated with K2CO3 to give 2.1 g. of the pure racemic form of XI. XI (1.4 g.) is subjected to column chromatog. (with 90:10 Bu2O-AcOH saturated with H2O on silica gel preheated for 12 hrs. at 115°) and crystallized from ligroine to give pure dl-XI m. 75-6°. XI (2.5 g.) was added to 30 ml. p-MeC6H4SO3H in C6H6 (prepared by adding 2 g. of the acid to 700 ml. C6H6 and distilling to obtain 30 ml. distillate) and refluxed 44 hrs. to yield I. I was also prepared from XI by reacting 0.704 g. XI with NaOEt (prepared from

L59 ANSWER 46 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
0.38 g. Na and 15 ml. EtOH) and 300 ml. sulfolane (prepd. over a mol. sieve) distg., and treating with HBr.
IT **23791-62-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23791-62-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 47 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1969:11302 CAPLUS
DOCUMENT NUMBER: 70:11302
TITLE: Total synthesis of the macrocyclic lactone, dideoxyzearalane
AUTHOR(S): Wehrmeister, Herbert L.; Robertson, Donald Edwin
CORPORATE SOURCE: Res. Dep., Commer. Solvents Corp., Terre Haute, IN, USA
SOURCE: Journal of Organic Chemistry (1968), 33(11), 4173-6
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Dideoxyzearalane, 2-(10-hydroxyundecyl)benzoic acid lactone (II), the simplest macrocyclic lactone having the same skeletal structure as the macrolide zearalenone (I), was totally synthesized. Condensation of 10-undecenoic anhydride with phthalic anhydride gave 3-(9-decenylidene)phthalide (III). The internal double bond of III was in effect reduced in alkali with NaBH4 and the terminal double bond was hydrated with Hg(OAc)2 and NaBH4 to yield 3-(9-hydroxydecyl)phthalide (IV). Saponification and catalytic hydrogenolysis of IV gave 2-(10-hydroxyundecyl)benzoic acid (V). (±)-I was obtained by lactonization of V in benzene at high dilution with COCl2 cyclization agent. Optically active (+)-I was obtained by hydrogenolysis of the dibenzoxazolyl ether of zearalane, derived from II. This (+)-I and the totally synthesized (±)-I are spectroscopically and chromatographically identical. 11 references.
IT **17393-28-1P 17397-59-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17393-28-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 14,16-bis(2-benzoxazolyloxy)-3,4,5,6,7,8,9,10,11,12-decahydro-3-methyl- (8CI) (CA INDEX NAME)



RN 17397-59-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-3-methyl-, (+)- (8CI) (CA INDEX NAME)

Rotation (+).

L59 ANSWER 47 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 48 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1968:506281 CAPLUS
DOCUMENT NUMBER: 69:106281
TITLE: Estrogenic compounds and animal growth promoters
INVENTOR(S): Hodge, Edward B.; Hidy, Phil H.; Wehrmeister, Herbert L.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3373039	A	19680312	US 1967-678177	19671026
NL 6814321	A	19690429	NL 1968-14321	19681007
GB 1249136	A	19711006	GB 1968-1249136	19681016
CH 552948	A	19740830	CH 1968-15847	19681023
BE 722960	A	19690401	BE 1968-722960	19681025
FR 96046	E	19720519	FR 1968-96046	19681025

PRIORITY APPLN. INFO.: US 1967-678177 19671026
GI For diagram(s), see printed CA Issue.
AB The compds. of this invention (I) exhibit estrogenic activity or aid in increasing the rate of growth in meat-producing animals, e.g., cattle, lamb, and swine. A mixture of 10 g. I (R = Me, X = H, Y = H, A = CH:CH, Q = CO) and 100 ml. cold concentrated HNO3 was stirred 2 hrs. to effect solution, poured over cracked ice, and filtered to give 3.7 g. I (R = Me, X = H, Y = NO2, A = CH:CH, Q = CO), m. 163-4° (MeOH). Similarly prepared was I (R = H, X = H, Y = NO2, A = CH:CH, Q = CO) (Ia), m. 206-8°. A mixture of 5.0 g. I (R = H, X = H, Y = H, A = CH2CH2, Q = CHOH) in 150 ml. AcOH was slowly added to 10 ml. cold concentrated HNO3, stirred 1 hr., poured into 1 l. H2O, and refrigerated to give I (R = H, X = Y = NO2, A = CH2CH2, Q = CHOH), m. 179-82°. Similarly prepared was I (R = H, X = Y = NO2, A = CH2CH2, Q = CO), m. 161-7°, and the 3,5-dinitrodeoxytetrahydro derivative (Ib) of I (R = H, X = Y = H, A = CH:CH, Q = CO). A mixture of 50 ml. concentrated (95%) H2SO4, 1.5 g. Ib, and 0.5 g. KNO3 was stirred 1 hr. in an ice bath, poured into 500 ml. H2O, and refrigerated to give Ia. Ia (2 g.) in 150 ml. EtOH was catalytically reduced at room temperature in the presence of 0.5 g. 5% Pd/C at 50 psi. H 3 hrs. to give I (R = H, X = H, Y = NH2, A = CH2CH2, Q = CO), m. 185-90°. The following I were similarly prepared (R, X, Y, A, Q, and m.p. given): Me, H, NH2, CH2CH2, CO, 139-44°; H, H, NH2, CH2CH2, CHOH, 258-65°. Also prepared was the 3,5-diaminodeoxytetrahydro analog of Ib. Ia (2 g.) was reduced as above, the reaction mixture treated with 1.5 ml. HCHO, catalytic reduction continued 3 hrs., the mixture filtered, the filtrate evaporated to dryness, and the residue crystallized from EtOH to give I (R = H, X = H, T = Me2N, A = CH2CH2, Q = CHOH). A mixture of 20 g. Ib in 20 ml. concentrated HNO3 was stirred 2 hrs., treated with 200 ml. cold H2O, and worked up in the usual manner to give I (R = H, X = NO2, Y = H, A = CH:CH, Q = CO), m. 147-50°. The filtrate from the latter yielded Ia. Formulations for pelleted rations

L59 ANSWER 48 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
contg. the above compds. as active ingredients are given.
IT **20453-89-8P 20453-93-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20453-89-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-13,15-dinitro- (8CI) (CA INDEX NAME)



RN 20453-93-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 13,15-diamino-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

L59 ANSWER 49 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L59 ANSWER 49 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1968:486653 CAPLUS
DOCUMENT NUMBER: 69:86653
TITLE: Estrogenic compounds
INVENTOR(S): Hodge, Edward B.; Hidy, Phil H.; Wehrmeister, Herbert L.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3373034	A	19680312	US 1967-620271	19670303
GB 1177695	A	19700114	GB 1967-1177695	19670518
IL 28005	A1	19710825	IL 1967-28005	19670518
BR 6790443	A0	19731226	BR 1967-190443	19670615
BE 700050	A	19671201	BE 1967-700050	19670616
NL 6708987	A	19680102	NL 1967-8987	19670628
CH 497133	A	19701015	CH 1967-497133	19670628

PRIORITY APPLN. INFO.: US 1966-561372 19660629
US 1967-620271 19670303

GI For diagram(s), see printed CA Issue.
AB I which may exhibit estrogenic activity in increasing the rate of growth of meat-producing animals were prepared. Thus I (R = Me, A = CH:CH, X = O) in Et2O added to PCl5 at 0° in an ice bath and the mixture stirred gave I (R = Me, X = Cl2, A = CH:CH) (Ia). I (R = Et, A = CH2CH2, X = O) treated as above gave I (R = Et, X = Cl2, A = CH2CH2). Treatment of Ia in Me2CO with KI gave the corresponding diiodo compound. Demethylation of Ia by heating at 120° in C6H6 with 2 equivs. AlCl3 gave I (R = H, X = Cl2, A = CH:CH). Also prepared were the following I (R, X, and A given): Me, H, Br, CH2CH2; Me, H, Cl, CH2CH2 (II). II was also treated with KI and demethylated as in an above example.
IT **19845-82-0P 19845-84-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19845-82-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 7-bromo-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dimethoxy-3-methyl- (8CI) (CA INDEX NAME)



RN 19845-84-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 7-chloro-3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dimethoxy-3-methyl- (8CI) (CA INDEX NAME)

L59 ANSWER 50 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1966:109113 CAPLUS
DOCUMENT NUMBER: 64:109113
ORIGINAL REFERENCE NO.: 64:20598f-h,20599a
TITLE: Estrogenic compounds and animal growth promoters
INVENTOR(S): Hodge, Edward B.; Hidy, Phil H.; Wehrmeister, Herbert L.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: 4 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3239341		19660308	US	19650215
NL 6601187			NL	

AB cf. following abstrs. I or II, where B is a fragment completing the ring with one C atom, have the title properties. These are derived from I (B = C:O, R = R' = H) (III)-which is prepared by fermentation. Thus, an innoculum of Gibberella zeae NRRL-2830 was prepared in two stages, first in 15 ml. Czapek-Dox solution and a small amount of agar at 25° for 168 hrs. and then, from this medium (washed with 5 ml. H2O), in 45 ml. Czapek-Dox solution at 25° for 96 hrs. This was added to a mixture of 300 g. finely divided corn and 150 ml. H2O and allowed to ferment in the dark and a H2O-saturated atmospheric at 25° for 20 days. Then 300 g. fermentation mixture was slurried with 500 ml. H2O, heated at 75° for 15 min., and filtered on filter aid. Extraction of 333 g. dried cake 4 times with 500 ml. EtOH and evaporation gave 6.84 g. crude solid, which was repeatedly extracted from 30 ml. CHCl3 into 5% Na2CO3, extracted 4 times at pH 6.2 into 75-ml. portions Et2O, and evaporated to 116 mg. residue. Counter-current distribution in a 2:2:4:1 CHCl3-CCl4-MeOH-H2O system gave pure III. Two 10-g. batches of III in 200 ml. HOAc mixed with 1.2 g. PdO hydrogenated at ambient temperature and 45 psi. followed by filtration and precipitation with 2 l. H2O gave 19.1 g. II(B = C:O, R = R' = H) (IV), m. 191-3°. One g. IV was slowly added to a chilled mixture of 5 ml. HSCH2CH2SH, 0.25 g. ZnCl2 (freshly fused), and 2 g. anhydrous Na2SO4. After 20 hrs. at 5° and 4 hrs. at ambient temperature, the reaction mixture was poured onto 50 ml. ice and the precipitate treated with 15 g. Raney Ni in 100 ml. 90% EtOH at reflux to give H (B = CH2, R = R' = H). Similarly prepared is I (B = CH2, R = R' = H). CH2N2 treatment affords p-Me (R' = Me) derivs., while Me2SO4 produces mixts. of o-Me (R = Me) and di-Me (R = R' = Me) derivs. O-Acetates are prepared with Ac2O-pyridine. Claimed are the following I (B, R, R', and m.p. given): C:O, H, Me, 120-2° (EtOH-H2O); CH2, H, Me, --; CH2, Ac, Me, --; C:O, Me, H, 169-74° (EtOH-H2O; CH2, Me, H, --, CH2, Me, Ac, --; C:O, Me, Me, 108-10° (60% EtOH); and CH2, Me, Me, --. Also claimed are the following II (R = R' = Me, B and m.p. given): C:O, 124-5.5° (71% EtOH); CH2, --.
IT **7396-62-5**, Benzoic acid, 2-(10-hydroxyundecyl)-4,6-dimethoxy-, μ-lactone **23791-62-0**, β-Resorcylic acid, 6-(10-hydroxyundecyl)-, μ-lactone
(manufacture by fermentation with Gibberella zeae)
RN 7396-62-5 CAPLUS

L59 ANSWER 50 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,11,10,12-decahydro-14,16-dimethoxy-3-methyl- (9CI) (CA INDEX NAME)



RN 23791-62-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-3-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 51 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN p-Anisic acid, 2-hydroxy-6-[10-hydroxy-6-(hydroxyamino)undecyl]-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



L59 ANSWER 51 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1966:103913 CAPLUS
DOCUMENT NUMBER: 64:103913
ORIGINAL REFERENCE NO.: 64:19503f-g
TITLE: Estrogenic compounds and animal growth promoters
INVENTOR(S): Hodge, Edward B.; Hidy, Phil H.; Wehrmaster, Herbert L.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: 3 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3239343		19660308	US	19650215

GI For diagram(s), see printed CA Issue.
AB I (B = CHNHOH) are prepared by hydrogenation with PdO catalyst of the appropriate oxime in MeOH at 750 psi. Thus, from the oxime, m. 202.5-5.5deg; (33% EtOH), is prepared I (R = R' = H). Similarly prepared are
I (R, R' given): Me, Me; Me, H; H, Me.
IT **5553-45-7**, β-Resorcylic acid, 6-[10-hydroxy-6-(hydroxyamino)undecyl]-, μ-lactone **5554-34-7**, o-Anisic acid, 4-hydroxy-6-[10-hydroxy-6-(hydroxyamino)undecyl]-, μ-lactone **5554-35-8**, p-Anisic acid, 2-hydroxy-6-[10-hydroxy-6-(hydroxyamino)undecyl]-, μ-lactone
(preparation of)
RN 5553-45-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1-one, 3,4,5,6,7,8,9,10,11,12-decahydro-14,16-dihydroxy-7-(hydroxyamino)-3-methyl- (9CI) (CA INDEX NAME)



RN 5554-34-7 CAPLUS
CN o-Anisic acid, 4-hydroxy-6-[10-hydroxy-6-(hydroxyamino)undecyl]-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



RN 5554-35-8 CAPLUS

L59 ANSWER 52 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1966:93190 CAPLUS
DOCUMENT NUMBER: 64:93190
ORIGINAL REFERENCE NO.: 64:17497d-e
TITLE: Estrogenic compounds and animal growth promoters
INVENTOR(S): Hodge, Edward B.; Hidy, Phil H.; Wehrmeister, Herbert J.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: 2 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3239347		19660308	US	19650215

AB cf. preceding and following abstrs. A solution of 368 mg. Ia in 8 ml. C5H5N and 5 ml. Ac2O was kept 16 hrs. at room temperature, treated with 25 ml. H2O, refrigerated 2 hrs., and worked up to give 120 mg. I (R = R1 = Ac, A = CH:CH), m. 115-17°. The above procedure in which half the Ac2O was used gave I (R = Ac, R1 = H, A = CH:CH). Similarly prepared was I (R = R1 = BuCO, A = CH:CH).
IT **5976-13-6**, β-Resorcylic acid, 6-(6-anilino-10-hydroxyundecyl)-, μ-lactone **5976-15-8**, β-Resorcylic acid, 6-[10-hydroxy-6-(methylamino)undecyl]-, μ-lactone **5976-18-1**, Benzoic acid, 2-[10-hydroxy-6-(methylamino)undecyl]-4,6-dimethoxy-, μ-lactone **5976-19-2**, β-Resorcylic acid, 6-(10-hydroxy-6-m-toluidinoundecyl)-, μ-lactone
(preparation of)
RN 5976-13-6 CAPLUS
CN β-Resorcylic acid, 6-(6-anilino-10-hydroxyundecyl)-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



RN 5976-15-8 CAPLUS
CN β-Resorcylic acid, 6-[10-hydroxy-6-(methylamino)undecyl]-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



RN 5976-18-1 CAPLUS
CN Benzoic acid, 2-[10-hydroxy-6-(methylamino)undecyl]-4,6-dimethoxy-, μ-lactone (7CI, 8CI) (CA INDEX NAME)

L59 ANSWER 52 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 5976-19-2 CAPLUS
CN β-Resorcylic acid, 6-(10-hydroxy-6-m-toluidinoundecyl)-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



L59 ANSWER 53 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1966:93189 CAPLUS
DOCUMENT NUMBER: 64:93189
ORIGINAL REFERENCE NO.: 64:17497c-d
TITLE: Estrogenic compounds and animal growth promoters
INVENTOR(S): Hodge, Edward B.; Hidy, Phil H.; Wehrmeister, Herbert L.
PATENT ASSIGNEE(S): Commercial Solvents Corp.
SOURCE: 4 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3239346		19660308	US	19650215

AB cf. preceding and following abstrs. A solution of Ib in 10% NaOH was treated with Me2SO4 in the usual manner to give I (R = R1 = Me, A = CH2CH2) (Ie). A mixture of 2.65 g. Ie, 50 ml. EtOH, 40 ml. C5H5N, and 3.5 g. hydroxylammonium chloride was refluxed 2 hrs., evaporated to 5-10 ml. volume, treated with 25 ml. H2O, and extracted with C6H6. The dried extract was evaporated and worked up to give 43 mg. III (R = R1 = Me, R2 = OH, A = CH2CH2) (IIIa), m. 130-2° (aqueous EtOH). IIIa was reduced using Raney Ni catalyst at 50 psi. H to the corresponding amine. Ia was similarly converted to the corresponding oxime III (R = R1 = H, R2 = OH, A = CH:CH) (IIIb), m. 202.5-5.5° (EtOH-H2O). IIIb was reduced to the amine as above. Id was similarly oximated. Ie and MeNH2 in the presence of H and Raney Ni gave IV (R = R1 = Me, R4 = H, R3 = NHMe, A = CH2CH2). Similarly prepared was IV (R = R1 = R4 = H, R3 = m-MeC6H4NH, A = CH2CH2).

IT **5976-01-2**, β-Resorcylic acid, 6-(6-amino-10-hydroxyundecyl)-, μ-lactone **5976-13-6**, β-Resorcylic acid, 6-(6-anilino-10-hydroxyundecyl)-, μ-lactone **5976-14-7**, Benzoic acid, 2-(6-amino-10-hydroxyundecyl)-4,6-diethoxy-, μ-lactone **5976-15-8**, β-Resorcylic acid, 6-[10-hydroxy-6-(methylamino)undecyl]-, μ-lactone **5976-17-0**, p-Anisic acid, 2-(6-amino-10-hydroxyundecyl)-6-hydroxy-, μ-lactone **5976-18-1**, Benzoic acid, 2-[10-hydroxy-6-(methylamino)undecyl]-4,6-dimethoxy-, μ-lactone **5976-19-2**, β-Resorcylic acid, 6-(10-hydroxy-6-m-toluidinoundecyl)-, μ-lactone **6009-94-5**, Benzoic acid, 2-(6-amino-10-hydroxyundecyl)-4,6-dimethoxy-, μ-lactone (preparation of)

RN 5976-01-2 CAPLUS
CN β-Resorcylic acid, 6-(6-amino-10-hydroxyundecyl)-, μ-lactone (7CI, 8CI) (CA INDEX NAME)

L59 ANSWER 53 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 5976-13-6 CAPLUS
CN β-Resorcylic acid, 6-(6-anilino-10-hydroxyundecyl)-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



RN 5976-14-7 CAPLUS
CN Benzoic acid, 2-(6-amino-10-hydroxyundecyl)-4,6-diethoxy-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



RN 5976-15-8 CAPLUS
CN β-Resorcylic acid, 6-[10-hydroxy-6-(methylamino)undecyl]-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



RN 5976-17-0 CAPLUS
CN p-Anisic acid, 2-(6-amino-10-hydroxyundecyl)-6-hydroxy-, μ-lactone (7CI, 8CI) (CA INDEX NAME)

L59 ANSWER 53 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 5976-18-1 CAPLUS
CN Benzoic acid, 2-[10-hydroxy-6-(methylamino)undecyl]-4,6-dimethoxy-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



RN 5976-19-2 CAPLUS
CN β-Resorcylic acid, 6-(10-hydroxy-6-m-toluidinoundecyl)-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



RN 6009-94-5 CAPLUS
CN Benzoic acid, 2-(6-amino-10-hydroxyundecyl)-4,6-dimethoxy-, μ-lactone (7CI, 8CI) (CA INDEX NAME)



L59 ANSWER 54 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1964:484184 CAPLUS
DOCUMENT NUMBER: 61:84184
ORIGINAL REFERENCE NO.: 61:14653b-e
TITLE: Constitution of monorden, an antibiotic with tranquilizing action
AUTHOR(S): McCapra, Frank; Scott, A. I.; Delmotte, P.; Delmotte-Plaquee, J.; Bhacca, N. S.
CORPORATE SOURCE: Univ. Brit. Columbia, Vancouver, Can.
SOURCE: Tetrahedron Letters (1964), (15-16), 869-75
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB correction of CA 61, 647c. Previously (CA 47, 5989h), the isolation of a new antibiotic from Monosporium bonorden was described and, on the basis of preliminary anal. data, the compound was assigned formula C17H16O7, and contained phenolic, acidic, and unsatd. functions. Reexamn. of the antibiotic, named monorden (I), by spectroscopic techniques now led to a revision of the formula and to a proposal of a complete structure of I. I had formula C18H17O6Cl, based on elemental analysis and inspection of the mass spectrum; diacetate m. 185-7°. Both I and its diacetate had infrared bands ascribable to aromatic and (or) double bond functions. From its mass, infrared, and ultraviolet spectra and double resonance nuclear magnetic resonance spectrum, a structure was proposed for I. I had strong antifungal properties and showed low toxicity, while acting as a potent sedative without other obvious effect on the nervous system. Direct comparison between radicicol (Mirrington, et al., CA 60, 10623g) and I showed their complete identity.
IT **100262-15-5**, Monorden, diacetate
(preparation of)
RN 100262-15-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 9,11-bis(acetyloxy)-8-chloro-1a,14,15,15a-tetrahydro-14-methyl- (9CI) (CA INDEX NAME)



L59 ANSWER 55 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1964:60728 CAPLUS
DOCUMENT NUMBER: 60:60728
ORIGINAL REFERENCE NO.: 60:10623g-h,10624g-h,10625a-b
TITLE: Constitution of radicicol
AUTHOR(S): Mirrington, R. N.; Ritchie, E.; Shoppee, C. W.; Taylor, W. C.; Sternhell, S.
CORPORATE SOURCE: Univ. Sydney
SOURCE: Tetrahedron Letters (1964), (7), 365-70
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. CA 58, 14058e. Extraction of the culture filtrate of a strain of Nectria radicicola (Gerlach and Nilsson, Phytopathol. Z. 48, 251(1963)] gave colorless crystalline radicicol (I, R = H)(II), m. 195°, [α]D 216° (c 1.0, CHCl3), γ 3300, 1655-1555 cm.-1 (Nujol), λ 265 mμ (ε 17,700, neutral or acidic alc.), λ 254, 274, 319 mμ (ε 22,600, 22,600, 15,000, alkaline alc.), methylated with MeI-K2CO3 to give the di-Me ether I (R = Me)(III), m. 186-7°, [α]D -58° (c 1.0, CHCl3). II catalytically hydrogenated yielded the tetrahydro derivative (IV, R = H)(V), m. 170-2°, [α]D -29° (c 1.0, CHCl3). Subtraction of the neutral ultraviolet curve of V from that of II gave the absorption λ 280 mμ (ε 12,000) characteristic of the dienone system -C:C C:C-C:O. Hydrogenation of III or methylation of V gave IV (R = Me)(VI), m. 134-6°, [α]D -83° (c 1.0, CHCl3). Acetylation of II yielded the di-Ac derivative (I) (R = Ac) (VII), m. 189-90°. Mild alkaline treatment of III gave 4-chloro-5,7-dimethoxyphthalide whose identity was established by synthesis from 3,2,4,6-ClMe(OH)2C6HCO2Et by methylation with MeI-K2CO3, bromination, saponification, and acid ring closure. The nature of 5 of the O atoms of II was accounted for; information that the 6th was linked in an epoxide was first obtained from nuclear magnetic resonance (n.m.r.) spectral detns. VI treated with HCO2H at 20° gave a glycol monoformate, hydrolyzed to yield the trans-diol (VIII), m. 250°, also prepared directly from VI by treatment with BF3 in BuOH. NaIO4 cleavage of VIII gave MeCH:CHCHO by βelimination, thus proving the relationship of the epoxide and ester functions and the presence of an Me group at C-2. Direct oxidation of VI with CrO3OAcOH gave adipic acid. Together with the other degradation products, the acid accounted for all of the C atoms of II. The signals in the n.m.r. spectra of II and its derivs. were exceptionally well resolved and a detailed interpretation was given in support of the assigned structure. Spin decoupling expts. confirmed the coupling of H-2 with a methylene proton at C-3 giving rise to the resonance at 2.4 p.p.m., of H-5 with H-6, and of H-4 with the methylene proton at C-3 resonating at 1.7 p.p.m. II appears to be derived biogenetically from acetate units in an unexceptionable manner. The structure of II was assigned by Scott and Bhacca to monorden, C17H16O7, m. 193.5°, [α] 20D 203° (CHCl3), isolated by Delmotte and Delmotte-Plaquee (CA 57, 5989h) from culture filtrates of Monosporium bonorden. The compds. were shown to be identical by comparison.
IT **75207-16-8**, Radicicol, O,O'-dimethyl- **88929-18-4**, Radicicol, tetrahydro- **100262-15-5**, Radicicol, diacetate **103064-90-0**, Radicicol, tetrahydro-O,O'-dimethyl-

L59 ANSWER 55 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(prepn. of)
RN 75207-16-8 CAPLUS
CN 6H-Oxireno[e](2)benzoxacyclotetradecin-6,12(7H)-dione, 8-chloro-1a,14,15,15a-tetrahydro-9,11-dimethoxy-14-methyl-, (1aR,2Z,4E,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 88929-18-4 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,4,5,14,15,15a-hexahydro-9,11-dihydroxy-14-methyl-, (1aR,14R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 100262-15-5 CAPLUS
CN 6H-Oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione, 9,11-bis(acetyloxy)-8-chloro-1a,14,15,15a-tetrahydro-14-methyl- (9CI) (CA INDEX NAME)



RN 103064-90-0 CAPLUS
CN 2H-Oxireno[e][2]benzoxacyclotetradecin-6,12(3H,7H)-dione, 8-chloro-1a,4,5,14,15,15a-hexahydro-9,11-dimethoxy-14-methyl- (9CI) (CA INDEX NAME)

L59 ANSWER 55 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)